Page 11234..1020..»

Archive for the ‘Skin Stem Cells’ Category

Cell Harvesting Systems Market: Increasing demand for stem cell transplantation along with stem cell-based therapy to drive the market – BioSpace

Cell Harvesting Systems: Introduction

Read Report Overview - https://www.transparencymarketresearch.com/cell-harvesting-systems-market.html

Market Dynamics of Global Cell Harvesting Systems Market

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=79522

Request for Analysis of COVID-19 Impact on Cell Harvesting Systems Market- https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1645

Cell Harvesting Systems Market: Segmentation

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=1645

Asia Pacific Cell Harvesting Systems Market to Expand Rapidly

Pre Book Cell Harvesting Systems Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=1645&ltype=S

Browse more Reports by Transparency Market Research:

Nucleic Acid Extraction Reagents Market: https://www.transparencymarketresearch.com/nucleic-acid-extraction-reagents-market.html

Osseointegration Implants Market: https://www.transparencymarketresearch.com/osseointegration-implants-market.html

Pancreatic Cancer Diagnostics Market: https://www.transparencymarketresearch.com/pancreatic-cancer-diagnostics-market.html

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

Mr. Rohit BhiseyTransparency Market Research

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

Follow this link:
Cell Harvesting Systems Market: Increasing demand for stem cell transplantation along with stem cell-based therapy to drive the market - BioSpace

The Medical Skin Care Products market to witness non-linear transition from 2017 to 2025 – Eurowire

Medical skin care products are used for beautifying or to address some other skin care problems. The cosmetic industry is booming and skin care forms a very huge part of this industry. The aesthetic appearance is so important that people spend a lot on skin care products and treatment. People being more technologically aware of the various new skin care products trending in the market. In addition to the aesthetic application, the medical skin care products are also used to address issues such as acne, pimples or scars.

Medical Skin Care Products Market: Drivers and Restraints

The medical skin care products is primarily driven by the need of natural based active ingredients products which are now trending in the market. Consumers demand medical skin care products which favor health and environment. Moreover, the consumers are updated with the trends so that various companies end up providing such products to satisfy the customers. For instance, a single product face mask has thousands of different variants. This offers consumers different options to select the product depending on the skin type. Moreover, the market players catering to the medical skin care products are offering products with advanced technologies. For instance, Santinov launched the CICABEL mask using stem cell material based on advanced technologies. The stem cells used in the skin care product helps to to protect and activate the cells and promote the proliferation of skin epidermal cells and the anagenesis of skin fibrosis.

To remain ahead of your competitors, request for a sample[emailprotected]

https://www.persistencemarketresearch.com/samples/18469

Medical Skin Care Products Market: Segmentation

On the basis of product type the medical skin care products market can be segmented as:

On the basis of application, the medical skin care products market can be segment as:

On the basis of distribution channel, the medical skin care products market can be segment as:

Medical Skin Care Products Market: Overview

Medical skin care products are used to address basic skin problems ranging from acne to scars. There are various advancements in the ingredients used to offer skin care products to the consumers. For instance, the use of hyaluronic acid and retinoids is the latest development in the industry. The anti-aging creams are at the forefront as the help treating issues such as wrinkles, scars, acne, and sun damage. Another, product in demand is the probiotic skincare which include lactobacillus and bifidobacterium.

To receive extensive list of important regions, Request Methodology here @

https://www.persistencemarketresearch.com/methodology/18469

Medical Skin Care Products Market: Region-wise Outlook

In terms of geography, medical skin care products market has been divided into five regions including North- America, Asia- Pacific, Middle-East & Africa, Latin America and Europe. North America dominated the global medical skin care products market as international players are acquiring domestic companies to make their hold strong in the U.S. LOral is accelerating its U.S. market by signing a definitive agreement with Valeant Pharmaceuticals International Inc. to acquire CeraVe, AcneFree and Ambi skin-care brands for US$ 1.3 billion. The acquisition is expected LOreal to get hold of the brands in the price-accessible segment. Asia Pacific is expected to be the fastest growing region owing to the increasing disposable income and rising awareness towards the skin care products.

Medical Skin Care Products Market: Key Market Participants

Some of the medical skin care products market participants are Avon Products Inc., Beiersdorf AG, Colgate-Palmolive Company, Kao Corporation, LOral S.A., Procter & Gamble, Shiseido Company, The Estee Lauder Companies Inc., Unilever PLC, Revlon, Clinique Laboratories, llc., Murad, LLC., SkinCeuticals, RMS Beauty, J.R. Watkins and 100% PURE.

You Can Request for TOC Here @https://www.persistencemarketresearch.com/toc/18469

Explore Extensive Coverage of PMR`s

Life Sciences & Transformational HealthLandscape

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Naved BegPersistence Market ResearchAddress 305 Broadway, 7th Floor, New York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Websitehttps://www.persistencemarketresearch.com

Original post:
The Medical Skin Care Products market to witness non-linear transition from 2017 to 2025 - Eurowire

Rejuvenating Austin spa puts holistic health and wellness on the table – CultureMap Austin

Every day, the average woman comes into contact with more than 500 harmful chemicals before she even leaves the house. After being absorbed into the body, these toxins can lead to health issues basically the opposite of what everyone is striving for right now.

EvolvE Cryo + Wellness founder Shannon Maddalena has made it her mission to soothe, revive, and nurture the body, from top to toe and inside and out.

"We strive to create a dialogue around health and holistic treatments to help reduce cortisol levels, improve immune function, reduce pain and inflammation, and increase energy and quality of sleep," she says. "If we are on a proactive path to become and stay healthy, we avoid working to correct sickness. If your immune system is prepared to fight off whatever the world throws at it, it is primed to do its job: keep you healthy."

Maddalena opened EvolvE nearly five years ago, and quickly became a go-to for Austinites looking for ways to clean up their bodies. Even professional athletes are on board the facility is the official wellness center of the Austin Bold soccer team.

But what really sets Evolve apart are its innovative treatments, all in a beautiful and relaxing atmosphere that send blood pressure dropping as soon as you walk in the door.

Here's a closer look at what is offered:

Infrared saunaThis holistic, comprehensive approach to detoxification can not only improve your skin's appearance, but also provide pain relief, improve circulation, support your immune system, and even reduce cellulite. Compared to a conventional sauna, infrared eliminates up to seven times more toxins by working at a cellular level, helping the heat penetrate deeper into your body and produce a more intense sweat. And with individual rooms, each session is completely private.

CryotherapyExposing your body to extreme cold induces a number of physiological changes. Initially, as the blood vessels constrict, blood moves away from the limbs and toward the vital organs. The immune system increases white blood cell count to fight viruses and bacteria, the circulatory system reacts to increased productivity, and inflammation and arthritis pain is significantly reduced.

In addition, the endocrine system jumps into action to release endorphins and norepinephrine that inflate "feel good" hormones in the blood stream. Studies have shown a reduction in cortisol and an increase in cold shock proteins, which protect the brain from both short- and long-term damage.

Body treatmentsThere's so much more than massage (though EvolvE certainly offers several relaxing options). The holistic treatments range from acupuncture, said to help with chronic pain and acute injury; to cupping, which increases circulation and calms the nervous system; to gua sha, a way to boost immunity and reduce inflammation.

There's as much science at EvolvE as there is Eastern holistic treatments, with photobiomodulation helping the body to absorb light energy to enhance tissue health at the cellular level. See? We really are just houseplants with more complicated emotions.

Skin treatmentsIt was important to Yarbrough that EvolvE only use the highest quality organic products featuring the world's most nutrient-dense, whole botanicals sourced from sustainable and ethical growers around the globe (and several local to Austin). Therefore, each signature skin treatment incorporates products that are botanically rich and nutrient dense, housing peptides, vitamin C, hyaluronic acid, marine algaes, and superfoods.

The Liquid Facelift, for example, infuses over 100 vitamins, minerals, and nutrients into the skin in an 80-minute treatment incorporating bioenergy, stem cells, and nanotechnology to brighten skin, reduce pores, and reverse the signs of aging.

"In the midst of a pandemic, there is a growing appetite for holistic health and a need to nurture not only the body, but the mind and spirit," says Maddalena. "We have to be our own advocates, because no one knows how it feels to be in our body. We know when something is even slightly off, and can take appropriate action from there."

EvolvE is located in the Austin hub of SoLA, just south of downtown at 3411 S. Lamar. Call512-326-2600 or visit its website to book a service.

Continue reading here:
Rejuvenating Austin spa puts holistic health and wellness on the table - CultureMap Austin

Impact Of Covid-19 on Cosmetic Skin Care Market 2020 Industry Challenges, Business Overview and Forecast Research Study 2026 – PRnews Leader

Cosmetic Skin Care Market Data and Acquisition Research Study with Trends and Opportunities 2019-2024The study of Cosmetic Skin Care market is a compilation of the market of Cosmetic Skin Care broken down into its entirety on the basis of types, application, trends and opportunities, mergers and acquisitions, drivers and restraints, and a global outreach. The detailed study also offers a board interpretation of the Cosmetic Skin Care industry from a variety of data points that are collected through reputable and verified sources. Furthermore, the study sheds a lights on a market interpretations on a global scale which is further distributed through distribution channels, generated incomes sources and a marginalized market space where most trade occurs.

Along with a generalized market study, the report also consists of the risks that are often neglected when it comes to the Cosmetic Skin Care industry in a comprehensive manner. The study is also divided in an analytical space where the forecast is predicted through a primary and secondary research methodologies along with an in-house model.

Download PDF Sample of Cosmetic Skin Care Market report @ https://hongchunresearch.com/request-a-sample/77005

Key players in the global Cosmetic Skin Care market covered in Chapter 4:HenkelNatura & CoKaoLaboratories IPRADMary KayBeiersdorfEste Lauder CompaniesCotyColgate-PalmoliveUnileverP&GShiseidoChanelJohnson & JohnsonAmorepacificRevlonKoseAvonLVMHL BrandsLOreal

In Chapter 11 and 13.3, on the basis of types, the Cosmetic Skin Care market from 2015 to 2026 is primarily split into:Anti-Aging Cosmetic ProductsSkin Whitening Cosmetic ProductsSensitive Skin Care ProductsAnti-Acne ProductsDry Skin Care ProductsWarts Removal ProductsInfants Skin Care ProductsAnti-Scars Solution ProductsMole Removal ProductsMulti Utility Products

In Chapter 12 and 13.4, on the basis of applications, the Cosmetic Skin Care market from 2015 to 2026 covers:Stem Cells Protection Against UVFlakiness ReductionRehydrate the Skin SurfaceMinimize wrinklesIncrease the viscosity of Aqueous

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2026) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:North America (Covered in Chapter 6 and 13)United StatesCanadaMexicoEurope (Covered in Chapter 7 and 13)GermanyUKFranceItalySpainRussiaOthersAsia-Pacific (Covered in Chapter 8 and 13)ChinaJapanSouth KoreaAustraliaIndiaSoutheast AsiaOthersMiddle East and Africa (Covered in Chapter 9 and 13)Saudi ArabiaUAEEgyptNigeriaSouth AfricaOthersSouth America (Covered in Chapter 10 and 13)BrazilArgentinaColumbiaChileOthers

For a global outreach, the Cosmetic Skin Care study also classifies the market into a global distribution where key market demographics are established based on the majority of the market share. The following markets that are often considered for establishing a global outreach are North America, Europe, Asia, and the Rest of the World. Depending on the study, the following markets are often interchanged, added, or excluded as certain markets only adhere to certain products and needs.

Here is a short glance at what the study actually encompasses:Study includes strategic developments, latest product launches, regional growth markers and mergers & acquisitionsRevenue, cost price, capacity & utilizations, import/export rates and market shareForecast predictions are generated from analytical data sources and calculated through a series of in-house processes.

However, based on requirements, this report could be customized for specific regions and countries.

Brief about Cosmetic Skin Care Market Report with [emailprotected]https://hongchunresearch.com/report/cosmetic-skin-care-market-size-2020-77005

Some Point of Table of Content:

Chapter One: Report Overview

Chapter Two: Global Market Growth Trends

Chapter Three: Value Chain of Cosmetic Skin Care Market

Chapter Four: Players Profiles

Chapter Five: Global Cosmetic Skin Care Market Analysis by Regions

Chapter Six: North America Cosmetic Skin Care Market Analysis by Countries

Chapter Seven: Europe Cosmetic Skin Care Market Analysis by Countries

Chapter Eight: Asia-Pacific Cosmetic Skin Care Market Analysis by Countries

Chapter Nine: Middle East and Africa Cosmetic Skin Care Market Analysis by Countries

Chapter Ten: South America Cosmetic Skin Care Market Analysis by Countries

Chapter Eleven: Global Cosmetic Skin Care Market Segment by Types

Chapter Twelve: Global Cosmetic Skin Care Market Segment by Applications 12.1 Global Cosmetic Skin Care Sales, Revenue and Market Share by Applications (2015-2020) 12.1.1 Global Cosmetic Skin Care Sales and Market Share by Applications (2015-2020) 12.1.2 Global Cosmetic Skin Care Revenue and Market Share by Applications (2015-2020) 12.2 Stem Cells Protection Against UV Sales, Revenue and Growth Rate (2015-2020) 12.3 Flakiness Reduction Sales, Revenue and Growth Rate (2015-2020) 12.4 Rehydrate the Skin Surface Sales, Revenue and Growth Rate (2015-2020) 12.5 Minimize wrinkles Sales, Revenue and Growth Rate (2015-2020) 12.6 Increase the viscosity of Aqueous Sales, Revenue and Growth Rate (2015-2020)

Chapter Thirteen: Cosmetic Skin Care Market Forecast by Regions (2020-2026) continued

Check [emailprotected] https://hongchunresearch.com/check-discount/77005

List of tablesList of Tables and Figures Table Global Cosmetic Skin Care Market Size Growth Rate by Type (2020-2026) Figure Global Cosmetic Skin Care Market Share by Type in 2019 & 2026 Figure Anti-Aging Cosmetic Products Features Figure Skin Whitening Cosmetic Products Features Figure Sensitive Skin Care Products Features Figure Anti-Acne Products Features Figure Dry Skin Care Products Features Figure Warts Removal Products Features Figure Infants Skin Care Products Features Figure Anti-Scars Solution Products Features Figure Mole Removal Products Features Figure Multi Utility Products Features Table Global Cosmetic Skin Care Market Size Growth by Application (2020-2026) Figure Global Cosmetic Skin Care Market Share by Application in 2019 & 2026 Figure Stem Cells Protection Against UV Description Figure Flakiness Reduction Description Figure Rehydrate the Skin Surface Description Figure Minimize wrinkles Description Figure Increase the viscosity of Aqueous Description Figure Global COVID-19 Status Overview Table Influence of COVID-19 Outbreak on Cosmetic Skin Care Industry Development Table SWOT Analysis Figure Porters Five Forces Analysis Figure Global Cosmetic Skin Care Market Size and Growth Rate 2015-2026 Table Industry News Table Industry Policies Figure Value Chain Status of Cosmetic Skin Care Figure Production Process of Cosmetic Skin Care Figure Manufacturing Cost Structure of Cosmetic Skin Care Figure Major Company Analysis (by Business Distribution Base, by Product Type) Table Downstream Major Customer Analysis (by Region) Table Henkel Profile Table Henkel Production, Value, Price, Gross Margin 2015-2020 Table Natura & Co Profile Table Natura & Co Production, Value, Price, Gross Margin 2015-2020 Table Kao Profile Table Kao Production, Value, Price, Gross Margin 2015-2020 Table Laboratories IPRAD Profile Table Laboratories IPRAD Production, Value, Price, Gross Margin 2015-2020 Table Mary Kay Profile Table Mary Kay Production, Value, Price, Gross Margin 2015-2020 Table Beiersdorf Profile Table Beiersdorf Production, Value, Price, Gross Margin 2015-2020 Table Este Lauder Companies Profile Table Este Lauder Companies Production, Value, Price, Gross Margin 2015-2020 Table Coty Profile Table Coty Production, Value, Price, Gross Margin 2015-2020 Table Colgate-Palmolive Profile Table Colgate-Palmolive Production, Value, Price, Gross Margin 2015-2020 Table Unilever Profile Table Unilever Production, Value, Price, Gross Margin 2015-2020 Table P&G Profile Table P&G Production, Value, Price, Gross Margin 2015-2020 Table Shiseido Profile Table Shiseido Production, Value, Price, Gross Margin 2015-2020 Table Chanel Profile Table Chanel Production, Value, Price, Gross Margin 2015-2020 Table Johnson & Johnson Profile Table Johnson & Johnson Production, Value, Price, Gross Margin 2015-2020 Table Amorepacific Profile Table Amorepacific Production, Value, Price, Gross Margin 2015-2020 Table Revlon Profile Table Revlon Production, Value, Price, Gross Margin 2015-2020 Table Kose Profile Table Kose Production, Value, Price, Gross Margin 2015-2020 Table Avon Profile Table Avon Production, Value, Price, Gross Margin 2015-2020 Table LVMH Profile Table LVMH Production, Value, Price, Gross Margin 2015-2020 Table L Brands Profile Table L Brands Production, Value, Price, Gross Margin 2015-2020 Table LOreal Profile Table LOreal Production, Value, Price, Gross Margin 2015-2020 Figure Global Cosmetic Skin Care Sales and Growth Rate (2015-2020) Figure Global Cosmetic Skin Care Revenue ($) and Growth (2015-2020) Table Global Cosmetic Skin Care Sales by Regions (2015-2020) Table Global Cosmetic Skin Care Sales Market Share by Regions (2015-2020) Table Global Cosmetic Skin Care Revenue ($) by Regions (2015-2020) Table Global Cosmetic Skin Care Revenue Market Share by Regions (2015-2020) Table Global Cosmetic Skin Care Revenue Market Share by Regions in 2015 Table Global Cosmetic Skin Care Revenue Market Share by Regions in 2019 Figure North America Cosmetic Skin Care Sales and Growth Rate (2015-2020) Figure Europe Cosmetic Skin Care Sales and Growth Rate (2015-2020) Figure Asia-Pacific Cosmetic Skin Care Sales and Growth Rate (2015-2020) Figure Middle East and Africa Cosmetic Skin Care Sales and Growth Rate (2015-2020) Figure South America Cosmetic Skin Care Sales and Growth Rate (2015-2020) Figure North America Cosmetic Skin Care Revenue ($) and Growth (2015-2020) Table North America Cosmetic Skin Care Sales by Countries (2015-2020) Table North America Cosmetic Skin Care Sales Market Share by Countries (2015-2020) Figure North America Cosmetic Skin Care Sales Market Share by Countries in 2015 Figure North America Cosmetic Skin Care Sales Market Share by Countries in 2019 Table North America Cosmetic Skin Care Revenue ($) by Countries (2015-2020) Table North America Cosmetic Skin Care Revenue Market Share by Countries (2015-2020) Figure North America Cosmetic Skin Care Revenue Market Share by Countries in 2015 Figure North America Cosmetic Skin Care Revenue Market Share by Countries in 2019 Figure United States Cosmetic Skin Care Sales and Growth Rate (2015-2020) Figure Canada Cosmetic Skin Care Sales and Growth Rate (2015-2020) Figure Mexico Cosmetic Skin Care Sales and Growth (2015-2020) Figure Europe Cosmetic Skin Care Revenue ($) Growth (2015-2020) Table Europe Cosmetic Skin Care Sales by Countries (2015-2020) Table Europe Cosmetic Skin Care Sales Market Share by Countries (2015-2020) Figure Europe Cosmetic Skin Care Sales Market Share by Countries in 2015 Figure Europe Cosmetic Skin Care Sales Market Share by Countries in 2019 Table Europe Cosmetic Skin Care Revenue ($) by Countries (2015-2020) Table Europe Cosmetic Skin Care Revenue Market Share by Countries (2015-2020) Figure Europe Cosmetic Skin Care Revenue Market Share by Countries in 2015 Figure Europe Cosmetic Skin Care Revenue Market Share by Countries in 2019 Figure Germany Cosmetic Skin Care Sales and Growth Rate (2015-2020) Figure UK Cosmetic Skin Care Sales and Growth Rate (2015-2020) Figure France Cosmetic Skin Care Sales and Growth Rate (2015-2020) Figure Italy Cosmetic Skin Care Sales and Growth Rate (2015-2020) Figure Spain Cosmetic Skin Care Sales and Growth Rate (2015-2020) Figure Russia Cosmetic Skin Care Sales and Growth Rate (2015-2020) Figure Asia-Pacific Cosmetic Skin Care Revenue ($) and Growth (2015-2020) Table Asia-Pacific Cosmetic Skin Care Sales by Countries (2015-2020) Table Asia-Pacific Cosmetic Skin Care Sales Market Share by Countries (2015-2020) Figure Asia-Pacific Cosmetic Skin Care Sales Market Share by Countries in 2015 Figure Asia-Pacific Cosmetic Skin Care Sales Market Share by Countries in 2019 Table Asia-Pacific Cosmetic Skin Care Revenue ($) by Countries (2015-2020) Table Asia-Pacific Cosmetic Skin Care Revenue Market Share by Countries (2015-2020) Figure Asia-Pacific Cosmetic Skin Care Revenue Market Share by Countries in 2015 Figure Asia-Pacific Cosmetic Skin Care Revenue Market Share by Countries in 2019 Figure China Cosmetic Skin Care Sales and Growth Rate (2015-2020) Figure Japan Cosmetic Skin Care Sales and Growth Rate (2015-2020) Figure South Korea Cosmetic Skin Care Sales and Growth Rate (2015-2020) Figure Australia Cosmetic Skin Care Sales and Growth Rate (2015-2020) Figure India Cosmetic Skin Care Sales and Growth Rate (2015-2020) Figure Southeast Asia Cosmetic Skin Care Sales and Growth Rate (2015-2020) Figure Middle East and Africa Cosmetic Skin Care Revenue ($) and Growth (2015-2020) continued

About HongChun Research: HongChun Research main aim is to assist our clients in order to give a detailed perspective on the current market trends and build long-lasting connections with our clientele. Our studies are designed to provide solid quantitative facts combined with strategic industrial insights that are acquired from proprietary sources and an in-house model.

Contact Details: Jennifer GrayManager Global Sales+ 852 8170 0792[emailprotected]

NOTE: Our report does take into account the impact of coronavirus pandemic and dedicates qualitative as well as quantitative sections of information within the report that emphasizes the impact of COVID-19.

As this pandemic is ongoing and leading to dynamic shifts in stocks and businesses worldwide, we take into account the current condition and forecast the market data taking into consideration the micro and macroeconomic factors that will be affected by the pandemic.

Cosmetic Skin Care :

HongChun Research, Cosmetic Skin Care , Cosmetic Skin Care market, Cosmetic Skin Care industry, Cosmetic Skin Care market size, Cosmetic Skin Care market share, Cosmetic Skin Care market Forecast, Cosmetic Skin Care market Outlook, Cosmetic Skin Care market projection, Cosmetic Skin Care market analysis, Cosmetic Skin Care market SWOT Analysis, Cosmetic Skin Care market insights

Continued here:
Impact Of Covid-19 on Cosmetic Skin Care Market 2020 Industry Challenges, Business Overview and Forecast Research Study 2026 - PRnews Leader

Next-gen skincare, silk without spiders and pollution for lunch: Meet the biotech startups pitching at IndieBios Demo Day – TechCrunch

Biotech can often, and sometimes literally, fly over our heads. However, the pandemic has shown an increased need for investment and focus on solutions that work on human and planetary health. For IndieBio, a science and biotech accelerator run by VC firm SOSV, this unprecedented year offered high stakes and new challenges.

Today and tomorrow, the biotech accelerator is hosting its twice-annual demo day.

Starting in 2015, IndieBio has provided resources to founders solving complex challenges with biotech, from fake meat to sustainability. Over the years, the accelerator has created a portfolio of biotech companies valued at over $3.2 billion, including companies like Memphis Meats, which develops cultured meat from animal cells; NotCo, a plant-based food brand; and Catalog, which uses organisms for data storage.

As part of the accelerator, each participating company receives $250,000 in capital, numerous other services and access to lab space. In July, the founder and head of IndieBio, Arvind Gupta, left his position to pursue a role at Mayfield. While Gupta remains an adviser,Po Bronson took the role as the new managing director.

Bronson was immediately put to the test. This year, the program expanded from operating solely in San Francisco to also create a cohort based in New York. It also doubled the amount of companies it invested in, bringing this cohort to 20 companies.

As you can imagine, lockdowns ultimately forced founders to delay key lab work in the beginning of the pandemic. Eventually, founders were able to partner with universities, contract research organizations or other biotech accelerators to begin their research, says Julie Wolf, the head of investor relations at SOSV. The NYC class received a golden ticket for free lab space come November.

And these dynamics make this cohort all the more fascinating to dive into.

Watch the New York Stream here, which will happen on Tuesday October 27 from 1:00-3:00pm ET.

Watch the San Francisco stream here, which will happen on Wednesday October 28 from 10:00-12:00pm PT.

For those who cant tune in, heres a list of all the companies presenting in New York and San Francisco over the next two days.

Reazent: Founded by Sumit Verma, Reazent has discovered and patented a way to manipulate soil bacteria into triggering crops to grow more. It works with 116 strains, from kale to potatoes, and wants to dig into the market of organic agricultural land.

Image Credits: Witthaya Prasongsin / Getty Images

Kraken Sense: Founded by Nisha Sarveswaran, Kraken Sense has created an in-line autonomous device to measure the concentration of pathogens in large-scale food and water systems. The product can be deployed in farms and kitchens and uses refillable single-use cartridges.

Advanced Microbubbles: The startup, led by Jameel Feshitan, has created a platform that helps practitioners deliver drugs to complex and difficult tumors. The company collaborated with NIH NIDA and uses proprietary bubbles to deliver chemotherapeutics. Currently, Microbubbles is working to solve two types of cancers: neuroblastoma and pancreatic cancer.

Cybele Microbiome:CEO Nicole Scott has created a direct-to-consumer skincare line with a focus on prebiotics. The line uses ingredients that work in tandem with the skin microbiome, even triggering it to express natural scents.

Ivy Natal:Ivy Natal is developing a process to harvest healthy human egg cells from skin cells. CEO Colin Bortner is working on a treatment for infertility and plans to enable families to have genetic children who cant otherwise with current solutions.

Microgenesis: Led by Gabriela Gutierrez, Microgenesis has created a proprietary test and nutraceutical regiment (including probiotics) to help women who struggle with infertility get pregnant. The company worked with a cohort of 287 mothers, and with its product over 75% of patients became pregnant.

Image Credits: Westend61 / Getty Images

AsimicA:Led by Nikolai Mushnikov, Asmicia has created a new way to bring stem cells to microbes. The company could lengthen and grow the yields of bio-manufacturing, and is currently working to select the right fermentation partner.

Liberum: CEO Aidan Tinafar is working to disrupt what they think could be a $400 billion market opportunity: recombinant proteins. Liberum has created a protein printer that could cut down the creation of custom recombinant proteins from weeks to a few hours.

Khepra:Led by Julie Kring, Khepra is leveraging fuel production as a way to store extra renewable energy. The company is building a series of reactors that could take your old plastic bottles and cardboard boxes, extract chemicals and fuels, and sell that fuel to refineries.

Carbix:Carbix, led by Quincy Sammy, takes enriched CO2 and converts it into raw material that can then be repurposed into industrial products.

Spintex: CEO Alex Greenhalgh is creating a new, scalable way of making silk. The company mimics spider spinning and uses a natural protein, with an end product that they see as better than premium silk.

Biomage:CEO Adam Kurkiewicz wants to make single-cell sequencing data more accessible for research biologistics. The technology could help scientists explore human cells to enhance medicine and drug discovery.

Diptera.ai: Vic Levitin is creating a scalable, affordable and sustainable way to fight mosquitoes and their diseases.

Cayuga Biotech:Damien Kudela, CEO of Cayuga Biotech, has created a drug that could induce clots and stop severe bleeding situations.

Brightcure:Chiara Heide, CEO of Brightcure, has created a bioactive cream that uses natural bacterium to restore a womans natural microbiome.

Multus Media:CEO Cai Linton is producing an ingredient that hopes to make cultivated meat production affordable and accessible.

Image Credits: Getty Images

BioFeyn:The company uses nanotechnologies based on human medicine to deliver nutrients and disease prevention to fish. CEO Timothy Bouley is working to make eating healthy fish a sustainable practice.

Halomine: Ted Eveleth, CEO, wants to turn every surface into an antimicrobial surface. Halomines product, Halofilm, can be used in tandem with any household bleach cleaner to enhance disinfection techniques.

Allied Microbiota:Lauralynn Kourtz, CEO of Allied Microbiota, wants to use natural microbes to eliminate toxic waste. The company uses bacteria to clean contaminated soils.

Scindo: Scindo, led by Gustaf Hemberg, uses enzymes to make plastic biodegradable.

Here is the original post:
Next-gen skincare, silk without spiders and pollution for lunch: Meet the biotech startups pitching at IndieBios Demo Day - TechCrunch

RenovaCare to Commence Investor Business and Financial Presentations; Webcast on October 29, 2020 – GlobeNewswire

RenovaCare Commences Investor Presentations

RenovaCare Commences Investor Presentations; Webcast on October 29, 2020 at 11:00 AM EDT

ROSELAND, N.J., Oct. 22, 2020 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR; http://www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, today announced that the Company will begin presenting business and financial updates, with the first scheduled for October 29, 2020 at 11:00 a.m. (EDT), to be held via online webcast.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3ab4ca73-7a9f-44f3-93f7-c2dd50571f3a

During the webcast, RenovaCare management will provide an overview of the Companys performance in 2020 year-to-date and also discuss its business objectives for 2021.

Interested investors, analysts and media representatives are invited to participate in the webcast via the following link:

Link to Register for RenovaCare Oct. 29, 2020 Investor Presentationhttps://edge.media-server.com/mmc/go/RenovaCare10292020

As investor engagement is important to RenovaCare, all interested parties will have the opportunity to ask questions by submitting them to investor_relations@renovacareinc.comby 3:30 p.m. eastern daylight time on October 28, 2020. Shareholders will also have the ability to ask questions during and following the presentation through a chat box with the presentation operator.

The webcast will be recorded and available for playback after the meeting through the RenovaCare website atwww.renovacareinc.com.

RenovaCarepatented investigative technologies are currently in development. They are not available for sale in the United States or elsewhere. There is no assurance that the Companys planned or filed submissions to the U.S. Food and Drug Administration or other regulatory authorities will be accepted or cleared.

About RenovaCareRenovaCare, Inc. is developing first-of-its-kind autologous (self-donated) stem cell therapies for the regeneration of human organs. Its initial product under development targets the bodys largest organ, the skin. The companys flagship technology, the CellMist System, uses its patented SkinGun to spray a liquid suspension of a patients stem cells the CellMist Solution onto wounds.

Over 70 patients with various types of second-degree burns have been treated on an experimental basis utilizing the technology underlying the Companys SkinGun, which RenovaCare has developed as a potential alternative to skin grafting and other treatment options. Sprayed with a gentle mist of their own skin cells, many of these patients left the hospital within days, avoiding generally painful skin graft surgeries and potentially prolonged hospitalization.

RenovaCare is developing its CellMist System as a promising new alternative for patients suffering from burns, chronic and acute wounds, and scars.

For additional information, please call Amit Singh at: 888-398-0202 or visit:https://renovacareinc.com

To receive future press releases via email, please visit:https://renovacareinc.com/investors/register/

Follow us on LinkedIn:https://www.linkedin.com/company/renovacare-inc-/Follow us on Twitter:https://twitter.com/RenovaCareIncFollow us on Facebook:https://www.facebook.com/renovacarercar

Social Media DisclaimerInvestors and others should note that we announce material financial information to our investors using SEC filings and press releases. We use our website and social media to communicate with our subscribers, shareholders and the public about the company, RenovaCare, Inc. development, and other corporate matters that are in the public domain. At this time, the company will not post information on social media that could be deemed to be material information unless that information was distributed to public distribution channels first. We encourage investors, the media, and others interested in the company to review the information we post on the companys website and the social media channels listed below:

* This list may be updated from time to time.

Legal Notice Regarding Forward-Looking StatementsNo statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although RenovaCare, Inc. (the Company) believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words may, will, should, could, expect, anticipate, estimate, believe, intend, or project or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: the timing and success of clinical and preclinical studies of product candidates, the potential timing and success of the Companys product programs through their individual product development and regulatory approval processes, adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, obsolescence of the Companys technologies, technical problems with the Companys research, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Companys operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Companys ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, and other risks. There can be no assurance that further research and development will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that the Company will be able to develop commercially viable products on the basis of its technologies. In addition, other factors that could cause actual results to differ materially are discussed in the Companys most recent Form 10-Q and Form 10-K filings with the Securities and Exchange Commission. These reports and filings may be inspected and copied at the Public Reference Room maintained by the U.S. Securities & Exchange Commission at 100 F Street, N.E., Washington, D.C. 20549. You can obtain information about operation of the Public Reference Room by calling the U.S. Securities & Exchange Commission at 1-800-SEC-0330. The U.S. Securities & Exchange Commission also maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the U.S. Securities & Exchange Commission athttp://www.sec.gov. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Continue reading here:
RenovaCare to Commence Investor Business and Financial Presentations; Webcast on October 29, 2020 - GlobeNewswire

Augustinus Bader on his revolutionary approach to skincare – Wallpaper*

Augustinus Bader on his revolutionary approach to skincare

The mind behind the most coveted products in beauty discusses thescience behind the brand

When Augustinus Bader first launched The Cream in 2018, it was hailed as a miracle. In a matter of weeks, it could transform any skin type within any age range, dispelling wrinkles, redness, dryness, scaring, visible pores, sagginess, and practically every other skin concern it would usually take a shelf load of serums to combat. While miraculous, magical, and other mystical attributions caneasily, and quite fairly, be applied to Augustinus Bader products, the real genius of the brand comes down to pure science.

The Augustinus Bader skincarebrand was the by-product of its namesakes development of medical-grade cream, which could heal severe burn injuries to an extent that was previously only possible through skin grafts. Professor Bader, a stem cell and biomedical scientist at Leipzig University, was hoping to get the cream backed by a pharmaceutical company but, in the words of his business partner Charles Rosier, clinical trials cost tens of tens of millions of dollarsand the majority of accidents around burns happen to children, often in third-world countries. For a pharmaceutical company, when the outcome is not necessarily the most profitable outcome, theres less interest.

Inspired to make Baders cream widely available, Rosier encouraged the Professor to translate the principles of his burn cream into skincare. In my mind, I thought, if we create a cream thats superior to whats on the market and its a big success, then he can focus on is research and we can finance the clinical trial.

Baders cream centred around one, revolutionary hypothesisthat the body already possesses all of the stem cells it needs to regenerate itself. The problem, when it comes to the skins inability to heal from severe injuries or just the everyday effects of ageing, is that the bodys ability to trigger those regenerative cells has been impeded.

Bader developed this hypothesis based on two observations. First, that the size of the wound affects the bodys ability to heal. Asmall paper cut heals quickly, while a large scale burn takes time to heal and often leaves scar tissue. Secondly, the body automatically knows where the site of an injury is. When you cut your left hand, your body immediately starts sending cells to the area of the cut so that the skin can rebuild. Yet,the same tissue would never rebuild on your right hand because it rebuilt on your left. Only where there is a wound is the body rebuilding.

In Baders words, If the cut is super small, you would have a small distance between the edges of the cut skin and the cells can still communicate over this small distances through the hand, and would close the wound. But if you burn your hand, the cells would be dying and the signal response cannot arrive at this injury. The response is totally different, the small cut heals perfectly, while on the other side the big injury kills this confirmation.

So the basis of [my] hypothesis is that this is probably just the absence of specific molecules that cannot arrive to the site of the injury because cells are dying or are blocked. So many, many years ago I started trying to find solutions to this problem because genetically speaking were the same human being, why would we have these limitations, why would we have these problems? It doesnt make any sense.

I thought, why not try to replace what the cells would be doing if they were present? That triggering complex, which singles the cells to respond to the injury, or, when it comes to skincarewrinkles, is the secret, miracle likeelement of Baders cream.

Unlike most skincare, which just changes the outside surface of the skin, Baders skincare works from the inside out, transforming the bodys internal, cellular communication for exterior changes. I think ageing is just a lack of repair, a lack of regeneration. Skin is a living organism, which has to be remodelled, meaning repaired a little bit everyday. But you can accelerate this repair lead.

Theres something super, super sensitive inside of you, which are these cells that sense the microenvironment and respond to the need. So the cream, in a way, is only a toolbox, which helps your stem cells when they sense this need to interact more appropriately.

This new approach to the effects of ageing is a revolution in skincare that, no doubt, heralds the beginning of a new science-driven, cellular-focused trend in the industry.

This year, Bader has launched a number of additional products to his line beyond The Cream and its companion The Rich Cream. The new additions include a Cleansing Gel, Face Oil, Body Cream and, as of today, Cleansing Balm with more releases set for the next year.

Visit link:
Augustinus Bader on his revolutionary approach to skincare - Wallpaper*

8 Skin-Boosting, Anti-Aging Treatments for Generation Xers and Beyond – NewBeauty Magazine

Getting up there in years comes with its drawbacks and benefits, and the onset of facial lines and volume loss that comes tends to top the list of drawbacks. You can count facial aging right up there with the onslaught of back pain and the occasional grey hair turning into a full head of silver. To soften those where did they come from facial lines and give skin a more youthful glow, these anti-agers target the main offenders: wrinkles and uneven skin tone and texture.

2/8

Glycolipids in Dr. Loretta Intense Replenishing Serum ($70) trash moisture on the skin surface to help hydrate skin while the antioxidant lipochroman combats free radicals and protects from harmful UV light, leaving skin looking plump, smooth and rejuvenated.

3/8

Apply a layer of Augustinus Bader The Face Oil ($230) morning and night. Utilizing Professor Baders TFC8 technology, the oil promotes cellular renewal, which helps smooth skin texture and reduce the look of fine lines and wrinkles.

4/8

The name says it all with ZO Skin Healths Firming Serum ($235). Lightweight and tolerable for even sensitive skin types, this anti-ager includes the brands ZCORE complex which consists of a synthetic tetrapeptideand sweet yellow clover to help strengthen skin laxity. Plant stem cells provide powerful antioxidant protection while sodium DNA helps stimulate cell repair and reduce inflammation.

5/8

Harnessing the brands signature ingredient, La Prairies Skin Caviar Liquid Lift ($690) blends two types of caviar, Premiere and Absolute, into a milky emulsion to deliver the perfect dose of serum that promises firmer skin and enhanced elasticity.

6/8

Bioeffect Limited Edition EGF Serum ($495) is said to have twice the original EGF formulas anti-aging benefits due to its inclusion of a rare black barley that is grown at the brands state-of-the-art greenhouse in Iceland. The EGF stands for Epidermal Growth Factor, which in this serum is totally plant derived and signals skin cells to prompt collagen and elastin production. The unique black obsidian bottle design was created by Icelandic artist Shoplifter.

At NewBeauty, we get the most trusted information from the beauty authority delivered right to your inbox

Find a NewBeauty "Top Beauty Doctor" Near you

Read more:
8 Skin-Boosting, Anti-Aging Treatments for Generation Xers and Beyond - NewBeauty Magazine

22 Best Night Creams 2020 for All Skin Types and Concerns – Greatist

Top notch ingredients are vital when it comes to creams. We chatted with skin care pros to see which ingredients are the best . This helped us pick out the products with the most oomph.

We also factored in:

Pricing guide

Night creams def have a rep for being expensive and some totally are. You should expect to pay more for extra bells and whistles (e.g. designer brands, fancy packaging, etc.). But thats definitely not the case percent of the time. You can find awesome, dermatologist-recommended products for around $10.

This guide will help you pick the best cream for your skin and budget:

$ = $10$20$$ = $25$50$$$ = $51$75$$$$ = over $76

Whether youre looking for a simple cream that gives your skin a glowy boost or a powerful cream for more mature skin to help reduce fine lines, theres a cream for you. Here are the top 22 night creams for every need.

Price: $$$$

Designed for all skin types, this lightweight cream uses retinol to reduce the appearance of lines. Hyaluronic acid delivers hydration and improves skins tone and texture. It also has niacinamides and picolinamides that support your skins natural barrier and lock in moisture.

Cons: Some peeps with sensitive skin said it caused irritation.

Buy Murad Retinol Youth Renewal Night Cream online.

Price: $

Unlike some heavy duty hydrators, this cream is oil-free and wont clog pores. You can use it day and night without worrying about pesky pimples.

It has the benefits of anti-aging while being lightweight enough to not trigger acne, says dermatologist Erum Ilyas, MD, MBE, FAAD. If youre looking for a cream but dont want to risk breakouts, this is a nice one to try.

Cons: It might not be hydrating enough for dry skin.

Buy OLAY Total Effects 7-in-1 Anti-Aging Moisturizer online.

Price: $$

Found: An overnighter that fights the signs of aging and keeps breakouts at bay. Retinol helps plump skin to reduce the appearance of lines and wrinkles. Salicylic and lactic acids keep bacteria from clogging pores and causing breakouts.

Cons: Salicylic acid can be drying.

Buy Arcona PM Blemish Lotion online.

Price: $$

This concentrated balm harnesses the power of colloidal oatmeal and sweet almond oil to soothe itchy, inflamed skin. It promotes a smoother and more even skin texture and can help reduce redness. Its even safe to use around your eyes and on your lids.

Cons: Some users found the rich texture to be a bit greasy.

Buy Skinfix Eczema Dermatitis Face Balm online.

Price: $$

This cream delivers heavy duty hydration to fight ashiness (thanks, avocado and shea butter). The vitamin C can help combat hyperpigmentation from exposure to UV rays (which is more likely in darker skin).

Cons: It might trigger breakouts in oily or acne-prone skin.

Buy Eve Hansen Vitamin C Night Cream online.

Price: $$

This super hydrating treatment straddles the line between cream and mask. Ingredients like squalene, glycerin, and fountain plant quench parched skin. It also helps protect the skins natural barrier to keep moisture in.

Cons: Some users complain that the texture is too thick to the point of being straight up sticky.

Buy Kiehls Ultra Facial Overnight Hydrating Masque online.

Price: $$$$

Dermatologist Deborah Longwill, DO, FAOCD, counts this potent potion as a current fave.

It combines the anti-aging ingredient resveratrol with antioxidant-rich ingredients like glycoin and ectoin, she explains.

These ingredients help shield your skin from environmental stresses. They also work to enhance elasticity, improve texture, and hydrate cells.

Cons: Its on the spendy side.

Buy Doctors Daughter Extremolyte Stem Cell Serum online.

Price: $$$

This hydrating-but-not-overly-heavy cream nourishes and plumps skin with ingredients like ceramides and hyaluronic acid. Oh, and its been clinically tested to reduce fine lines, dryness, and loss of firmness in just 7 nights.

Cons: Steer clear if youre not a lavender fan.

Buy IT Cosmetics Confidence in Your Beauty Sleep Night Cream online.

Price: $$

Does added fragrance irritate your skin? Same. Thankfully, this non-irritating cream that gets the job done. Its also loaded with vitamin E which fights redness and inflammation.

Cons: This cream is definitely on the thick side. It might feel heavy on oily skin.

Buy Olay Regenerist Night Recovery Anti-Aging Face Moisturizer online.

Price: $

Retinols a go-to ingredient for minimizing the appearance of fine lines thanks to its ability to protect the skin-plumping protein collagen.

It also has hyaluronic acid, a moisturizer to help prevent irritation and dryness that may be a better option for those with dry or sensitive skin, says dermatologist Susan A. Bard, MD.

Cons: Some users report experiencing redness or rashes.

Buy Neutrogena Rapid Wrinkle Repair Night Moisturizer online.

Price: $$$

This cream uses bakuchiol, a natural retinol alternative. Thats good news if you have sensitive skin.

Its a functional analog of retinol meaning it has the same effect, with one huge advantage: Its less irritating because its also an anti-inflammatory agent, Ilyas says.

Cons: Its got a strong peachy scent that you might love or hate.

Buy OLEHENRIKSEN Goodnight Glow Retin-Alt Sleeping Crme online.

Price: $

Ahhh. Heres a cooling gel cream made with licochalcone, a licorice-based skin soother. It fights redness and irritation in folks with sensitive, rosacea-prone skin. The creams noncomedogenic so it wont clog your pores either.

Cons: This stuffs very gentle. But it still might be too strong on super sensitive skin. Def do a patch test before slathering it all over your face.

Buy Eucerin Redness Relief Night Cream online.

Price: $

Bard loves recommending this simple, no-frills wrinkle fighter to patients. Its inexpensive, easy to find at most drugstores, and it works.

It contains retinol which helps improve fine lines and wrinkles, stimulate collagen production and decrease pigmented spots, she says.

Cons: The retinol in this formula is designed for daily use. But its still worth starting off gradually and work your way up. This gives your skin time to adjust.

Buy RoC Retinol Correxion Deep Wrinkle Night Cream online.

Price: $$

Lotus and peach extract fight oxidative stress and keep your skin looking glowy. But what really sets this lightweight cream apart is the floral peach aroma that comes wafting out the second you open the jar. Another perk: Its good for all skin types.

Cons: Its not formulated to fight fine lines or wrinkles.

Buy Lotus Youth Preserve Dream Face Cream online.

Price: $$$

Grease is not the word here. The gel formula delivers hydration but its still light and cooling. Its got niacinamide, viniferine, and natural pearlizers to fight the appearance of dark spots even out skin tone.

Cons: Some peeps said it didnt brighten their skin.

Buy Caudalie Vinoperfect Instant Brightening Moisturizer online.

Price: $$$

TBH the whole women vs. men products thing is silly. Right? But this cream feels a bit more manly thanks to the neutral packaging and woodsy scent. It fights fine lines and wrinkles with retinol and uses the antioxidant ferulic acid to combat dark spots and sun damage.

Cons: The heavy-duty retinol can be a little harsh especially if your skins not used to it.

Buy Dr. Dennis Gross Ferulic + Retinol Moisturizer online.

Price: $$

Glycolic acid is great at reducing the appearance of dark spots because it can suppress the production of melanin. The acid improves skins elasticity and boosts firmness too. So its an all-around awesome fountain of youth-kinda option.

Cons: Its a serum. If youre looking for hydration, youll still want to layer a moisturizer over top.

Buy Bolden Nighttime Repair Serum with 10% Glycolic Acid online.

Price: $$

Vitamin C and collagen are your eyes BFF. They brighten and plump the delicate skin around your peepers. This ones got both and a little goes a long way.

Cons: Its thick and rich. So it might clog your pores if it ends up on your T-zone.

Buy OLEHENRIKSEN Banana Bright Eye Cream online.

Price: $$$

This certified-organic cream boasts vitamin C, fruit stem cells, grape-seed oil, and squalene. It will brighten and hydrate without the use of parabens, petroleum, sulfates, pesticides, or phthalates.

Cons: The grape-seed oil might be too much for oily or acne-prone skin.

Buy Juice Beauty Stem Cellular Anti-Wrinkle Overnight Cream online.

Price: $

You can legit get amazing results from a night cream without spending megabucks. This dermatologist-developed moisturizer plumps and renews skis with a peptide complex. It also restores the skins natural barrier with essential ceramides. Plus its not greasy!

Cons: This is definitely a utilitarian option. If you love extras like scents or pretty packaging, skip it.

Buy CeraVe Skin Renewing Night Cream online.

Price: $

The suns UV rays can seriously stress your skin. This can cause dark spots, discoloration, and fine lines. But ingredients like green tea and vitamin C help fight sun-induced stress. This hydrating cream delivers both.

Cons: The packaging looks like it came from 1995, which, depending on what youre going for might ruin your #shelfie. (Or maybe not.)

Buy LILY SADO TEA+C Green Tea + Vitamin C Moisturizer online.

Price: $

Snow mushroom and sodium hyaluronate deliver mega moisture, while soothing lavender oil and chamomile extract help you chill and unwind. After anointing yourself with this vegan lotion, you might just wanna close your eyes and doze off.

Cons: You wont get as much anti-aging action here.

Original post:
22 Best Night Creams 2020 for All Skin Types and Concerns - Greatist

How Clinique La Prairie Is Keeping Humanity Fashionably Healthy In The Age Of Covid – Forbes

MONTREUX, SWITZERLAND - the Clinique La Prairie facility

Fashion, beauty, health and wellness are all intertwined. You cant really have one without the other

The Clinique La Prairie (CLP) in Montreux, Switzerland has been purveyors of luxury health and wellness for 89 years. This is Switzerlands thing, and one of the main reasons why people travel to the scenic nation of wellness facilities, mountains and natural springs because the country knows and understands the value of health and wellness, especially in this time of Covid. There are facilities like CLP all over Switzerland, with expert and advanced care that offer an intimate luxury environment. For CLP, its their mission to partner with visitors by providing personalized treatment to help and inspire people to live longer, healthier and better lives.

Our vision is always looking at pioneering longevity, says Simone Gibertoni, the CEO of CLP. As the future of wellness is linked to epigenetics, genomics, mental wellness and many more inspiring sciences, we are also taking a particular interest in research on microbiota, senescent cells and their markers, stress and sleep, circadian rhythms- among other aspects of life science and biology, in an effort to determine how they can be used to promote holistic longevity. This approach is envogue and the most fashionable lifestyle implementation that an individual can make in an effort to promote self-longevity.

So, how has this facility overlooking Lake Geneva been able to carry on a mission and vision of world class wellness- with the aim of opening up CLP facilities in Bangkok and Madrid this year, and, other facilities throughout the Middle East, Asia and the Americas in the future? From its inception in 1931 by Professor Paul Niehans, who pioneered development cell therapy, CLP almost ninety years later has continued to expand due to top health and wellness innovations. With fifty specialists, wellness programs that range from immune-boosting and anti-aging revitalization, and luxury hospitality all combined in a state-of-the-art facility, the clinic has been able to grow after all this time and keep people living longer in the process.

MONTREUX, SWITZERLAND - the Clinique La Prairie facility

We believe that health is not only the absence of illness, but the balance of mind, spirit and body, continues Gibertoni.Our guests have the privilege of being accompanied and advised in the ultimate refinement, and benefit from the expertise of leading specialists, from renowned doctors to experts in sport, wellness, and nutrition.

Pioneering health and wellness in the age of covid

As CLP is leading in immunity, they know this is on everyones mind this year, and they are seeing a demand of people wanting revitalization programs, a type of holistic offering that boosts the immune system, while upgrading the mind and body notes Gibertoni. In response to COVID-19, we have introduced new elements to it, including immuno-fortifying ingredients, enhanced nutrition coaching and wellness solutions to help activate the immune function, Gibertoni says. In its one-week approach, Revitalization helps to combat stress and infections and to improve health related setbacks. The Revitalization has been carried out exclusively at CLP for nearly nine decades and does include the CLP Extract, containing biologically active substances, given in conjunction with bio-stimulants.

Recognizing that todays lifestyle can attack the immune system, CLPs MASTER DETOX program provide solutions. Stress, food treated with pesticides, overconsumption and demanding situations like the current one exposes us to a vast quantity of toxins which affect our bodies regeneration capabilities, which can lead to fatigue, digestive problems, allergies or a weakened immune system, says Gibertoni. And in the age of Covid, these negative factors are a need for the body to be eliminated of toxins and promote physiological balance. In this new MASTER DETOX week, we focus on a Cellular Genomic detoxification protocol, in line with our scientific approach, and as always on individual plans based on the four pillars of medical, nutrition, wellbeing and movement.

MONTREUX, SWITZERLAND - the Clinique La Prairie facility offers one-on-one services about the state ... [+] and health of your body and how to increase longevity.

Fashion and beauty start with wellbeing

Gibertoni gives a fitting example of how beauty is birthed out of a good wellbeing regiment.

The first: every health and wellbeing program is also about revealing beauty, because each creates a bespoke path to feel good inside and out. What you eat, your level of stress, your lifestyle habits, your sleep quality, your possible vitamins deficiencies, ... these are all factors very directly impacting beauty.

For example, nutrition based on antioxidants and nutrients that help reduce internal inflammation will support protection against free radical effects and promote hydration. Through individual consultations about longevity, DNA insights, nutrition and movement, and of course body and skin advanced treatments, many factors are addressed in a holistic way during the week program that the guest spends at CLP, leading to help restore healthy foundations and routines, and ultimately boosting radiance.

MONTREUX, SWITZERLAND - the Clinique La Prairie facility offers holistic treatments like massages.

For CLP, revitalization and their MASTER DETOX program has been tried and tested against a radical anti-aging and medical science, so their programs have been able to stand the test of time with their treatments, technologies and coaching that amplify a persons wellbeing.

The most top fashion model, designer, and fashion connoisseur cant have a successful run at fashion without a proper health and wellness regimen, and an occasional visit to a clinic like CLP if they can afford it.

The second dimension is about CLPs cutting-edge programs that focus specifically on anti-aging and regenerative medicine, with an integrative approach to rejuvenation. We help realize the personal journey to look, feel and live well, with cutting edge anti-aging aesthetics protocols for men and women, where all aspects of the body and face are taken into consideration.

MONTREUX, SWITZERLAND - the Clinique La Prairie facility

They do this through stem cell-based programs of the likes of their Beauty Stem Cells and Cell Boast Facelift, where an individuals own stem cells are clinically harvested and re-injected and they also revitalize the skin using natural resources from ones own body to regenerate and slow down aging. All of this results in restoring a persons youthful appearance. Non-invasive aesthetic medicine delivers the latest solutions in the advancing field of preventive and restorative aesthetics. And their 4-5-day beauty holistic programs utilize a holistic approach to beauty by using non-invasive technologies from CLPs anti-aging research.

We all know the latest runway collections are envogue and we all want to look fashionable and have our beauty top notch. What we do for our bodies, from what we put into it and how we treat it will result in our beauty and make us illuminate our various and unique fashion styles. CLP gets people there by going deeper and under the surface by identifying nutritional and lifestyle changes that their visitors need to implement into their lives. All of this leaves people looking radiant, sculpted, balanced and more youthful by the time they leave our facility, as Gibertoni points out and it provides long-lasting effects.

Find out more about Clinique La Prairie in Montreaux and stay tuned for their upcoming new location openings- here.

Read more:
How Clinique La Prairie Is Keeping Humanity Fashionably Healthy In The Age Of Covid - Forbes

New research reveals why low oxygen damages the brain – Science Codex

CLEVELAND--Brain cell dysfunction in low oxygen is, surprisingly, caused by the very same responder system that is intended to be protective, according to a new published study by a team of researchers at the Case Western Reserve University School of Medicine.

"These powerful protein responders initially protect brain cells from low oxygen as expected, but we find that their prolonged activity leads to unintended collateral damage that ultimately impairs brain cell function," said the study's principal investigator Paul Tesar, a professor in the Department of Genetics and Genome Sciences at the Case Western Reserve School of Medicine and the Dr. Donald and Ruth Weber Goodman Professor of Innovative Therapeutics.

Defining the mechanism of brain-cell damage in low oxygen conditions provides an opportunity to develop effective therapies, including a class of drugs studied in their research that could inform future clinical approaches for many neurological diseases caused by low oxygen. The work also clarifies how the response to low oxygen causes disease in other tissues outside the brain.

Their research was published online Oct. 21 in the journal Cell Stem Cell.

The body's response to low oxygen

With the dawn of an oxygenated atmosphere, a burst of multicellular life was possible, as oxygen could be used to produce the energy needed to support complex life functions. Given the requirement of oxygen for life, nearly all organisms evolved a mechanism to rapidly respond to low oxygen--a condition called hypoxia. The Noble Prize in Physiology or Medicine was awarded in 2019 for discoveries of how cells in our body sense low oxygen levels and respond to stay alive.

At the core of this ancient response are proteins called hypoxia-inducible factors (HIFs), which instruct the cell to minimize oxygen consumption and maximize their access to oxygen. In this way, HIFs can be thought of as valiant heroes attempting to protect and resuscitate cells in the immediate response to low oxygen.

Prolonged hypoxia causes dysfunction in many tissues. In particular, stem cells in the brain are impaired by hypoxia in many diseases, including stroke, cerebral palsy related to premature birth, respiratory distress syndromes, multiple sclerosis and vascular dementia. Even the significant neurological damage caused by COVID-19 is attributed to hypoxia.

Until now, the precise causes of cell malfunction due to low oxygen were unknown.

The dark side of the hypoxia response

In this study, researchers developed a new approach to closely study how the hypoxia responder proteins function. By comparing how they work in brain-stem cells with other tissues, such as heart and skin, the scientists confirmed that the hypoxia responder proteins perform a beneficial function to promote cell survival in low oxygen in all tissues. However, these same hypoxia responder proteins had a previously unappreciated dark side, as they also switched on other cellular processes outside of the core beneficial response.

The team then demonstrated that this additional--and previously unknown--response is what impaired brain-stem cell function. This suggests that, while hypoxia responder proteins evolved to promote cell survival in all tissues of the body in low-oxygen conditions, their powerful effects can also have unintended consequences to disrupt cell function.

New opportunities for treating hypoxia damage

The authors tested thousands of drugs to try to restore brain-stem cell function to overcome the damaging effects of the hypoxia responder proteins. They discovered a group of drugs that specifically overcome the damage-inducing response, while leaving the beneficial response intact.

"One of the exciting avenues that stems from this work is identifying drugs that specifically target the damaging side of the hypoxia response while sparing the beneficial side," said first author Kevin Allan, a graduate student in Case Western's Medical Scientist Training Program. "This offers a new perspective on combating tissue damage due to hypoxia."

"Whether the damaging side of the hypoxia response is solely an unintended pathological effect or potentially a previously undiscovered normal process that goes awry in disease remains unknown," Tesar said. "Our work opens the door to a new way of thinking about how cells respond to low oxygen in health and disease."

Read the original post:
New research reveals why low oxygen damages the brain - Science Codex

Vanderbilt researchers make counterintuitive discoveries about immune-like characteristics of cells, chemotherapys impact on tissue growth -…

Vanderbilt University researchers have reported the counterintuitive discovery that certain chemotherapeutic agents used to treat tumors can have the opposite effect of tissue overgrowth in normal, intact mammary glands, epidermis and hair follicles. The researchers also are the first to report the discovery of an innate immune signaling pathway in fibroblaststhe spindle-shaped cells responsible for wound healing and collagen productionthat causes cells to proliferate. Such signaling pathways previously were attributed only to immune cells.

The article describing the research, DNA Damage Promotes Epithelial Hyperplasia and Fate Mis-specification via Fibroblast Inflammasome Activation, was published in the journal Developmental Cell on Oct. 13.

The findings of this work, led by postdoctoral fellow Lindsey Seldin and Professor and Chair of the Department of Cell and Developmental Biology Ian Macara, have broad implications for diseases associated with the immune system like psoriasis, as well as cancer and stem cell research.

Understanding the functionality of stem cells and the way that their behavior is regulated has been a longstanding research interest for Seldin. Normal stem cells have an amazing ability to continuously divide to maintain tissue function without forming tumors, she explained. We wanted to understand what happens to these cells in their native environment when subjected to damage, and if the response was connected to a specific tissue.

By testing perturbations to the epidermis, mammary gland and hair follicles vis--vis mechanical damage or DNA damage through chemotherapeutic agents, the researchers saw a paradoxical response: Stem cells, which otherwise would divide slowly, instead divided rapidly, promoting tissue overgrowth.

When the tissues were subjected to DNA damage, their stem cells overly proliferated, giving rise to different cells than they normally would. This was a very perplexing result, said Seldin, the papers lead author. We were determined to figure out if this was a direct response by the stem cells themselves or by inductive signals within their environment. The key clue was that stem cells isolated from the body did not behave the same way as in intact tissuean indication that the response must be provoked from signals being sent to the stem cells from other surrounding cell types.

The investigators turned their attention to fibroblasts, the predominant component of the tissue microenvironment. When fibroblasts in the epidermis were removed, the stem cell responsiveness to DNA damage was diminished, indicating that they played an important role. RNA sequencing revealed that fibroblasts can signal by way of inflammasomescomplexes within cells that help tissues respond to stress by clearing damaged cells or pathogens, which also in this case caused stem cells to divide. This is an astounding discovery, said Macara. Inflammasome signaling has previously been attributed only to immune cells, but now it seems that fibroblasts can assume an immune-like nature.

Seldin intends to replicate this work in the mammary gland to determine whether fibroblasts initiate the same innate immune response as in the epidermis, and more broadly how fibroblasts contribute to the development of cancer and other diseases associated with the immune system.

This work was supported by NCI/NIH grants R35CA132898, F32CA213794 and T32CA119925, as well as American Cancer Society grant PF-18-007-01-CCG.

Original post:
Vanderbilt researchers make counterintuitive discoveries about immune-like characteristics of cells, chemotherapys impact on tissue growth -...

Cosmetic Skin Care Market (Covid 19 Impact Analysis) Data Highlighting Major Vendors, Promising Regions, Anticipated Growth Forecast To 2027 -…

Global cosmetic skin care market is set to witness a substantial CAGR of 5.5% in the forecast period of 2019- 2026. The report contains data of the base year 2018 and historic year 2017. Increasing self-consciousness among population and rising demand for anti- aging skin care products are the factor for the market growth.

Global Cosmetic Skin Care Market By Product (Anti-Aging Cosmetic Products, Skin Whitening Cosmetic Products, Sensitive Skin Care Products, Anti-Acne Products, Dry Skin Care Products, Warts Removal Products, Infant Skin Care Products, Anti-Scars Solution Products, Mole Removal Products, Multi Utility Products), Application (Flakiness Reduction, Stem Cells Protection against UV, Rehydrate the skins surface, Minimize wrinkles, Increase the viscosity of Aqueous, Others), Gender (Men, Women), Distribution Channel (Online, Departmental Stores and Convenience Stores, Pharmacies, Supermarket, Others), Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Industry Trends and Forecast to 2026

Interpret a Competitive Outlook Analysis with Sample Report: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-cosmetic-skin-care-market&dw

Market Definition: Global Cosmetic Skin Care Market

Cosmetic skin care is a variety of products which are used to improve the skins appearance and alleviate skin conditions. It consists different products such as anti- aging cosmetic products, sensitive skin care products, anti- scar solution products, warts removal products, infant skin care products and other. They contain various ingredients which are beneficial for the skin such as phytochemicals, vitamins, essential oils, and other. Their main function is to make the skin healthy and repair the skin damages.

Market Drivers:

Market Restraints:

Key Benefits:

Make an Enquiry before Buying @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-cosmetic-skin-care-market&dw

Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of industry in these regions, from 2020 to 2027, covering

Global cosmetic skin care market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of cosmetic skin care market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Few of the major competitors currently working in the global cosmetic skin care market are LOral, Unilever, New Avon Company, Este Lauder Companies, Espa, Kao Corporation, Johnson & Johnson Services, Inc., Procter & Gamble, Beiersdorf, THE BODY SHOP INTERNATIONAL LIMITED, Shiseido Co.,Ltd., Coty Inc., Bo International, A One Cosmetics Products, Lancme, Clinique Laboratories, llc., Galderma Laboratories, L.P., AVON Beauty Products India Pvt Ltd, Nutriglow Cosmetics Pvt. Ltd, Shree Cosmetics Ltd among others.

Cosmetic Skin Care Market: Key Questions Answered in Report

The research study on the Cosmetic Skin Care market offers inclusive insights about the growth of the market in the most comprehensible manner for a better understanding of users. Insights offered in the Cosmetic Skin Care market report answer some of the most prominent questions that assist the stakeholders in measuring all the emerging possibilities.

Thank you for reading our report. For further queries, kindly get in touch with us and our team will provide excellent assistance in customization of the report according to your requirements

Read more @ https://www.databridgemarketresearch.com/reports/global-cosmetic-skin-care-market?dw

Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market ResearchUS: +1 888 387 2818UK: +44 208 089 1725Hong Kong: +852 8192 7475Email @ Corporatesales@databridgemarketresearch.com

Read the original post:
Cosmetic Skin Care Market (Covid 19 Impact Analysis) Data Highlighting Major Vendors, Promising Regions, Anticipated Growth Forecast To 2027 -...

Biotechs longevity obsession reaches the beauty industry – Glossy

As research on longevity has become a fixation of biotech startup investors, newly launched skin-care startup OneSkin is bringing it to the world of beauty.

Launching today via DTC e-commerce, the company is bridging the worlds of biotech and beauty after four years in development by a team of scientists. Coming out of the Bay Area-based biotech startup incubator MBC BioLabs, the brand has secured $7.5 million in VC and angel funding from sources including science accelerator IndieBio, SOSV and 2FutureHolding. The companys board includes prominent investor Peter Diamandis.

The brand is launching with one moisturizer it calls a topical supplement, which is available online for $100 for a 50-milliliter bottle via a subscription or $120 with one-time purchase. Some of the promised results are typical of beauty products: firmness, smoothness, hydration and collagen production, based on the results of a clinical trial. Its main differentiation point, however, is that it can reduce the biological age of the skin through a patented peptide it created called OS-01. The brand states it does this by preventing the accumulation of senescent cells that cause aging. The brand ran a 3-month clinical trial ending in March 2020 that was found to improve aesthetic features such as elasticity and wrinkles. To address the biological age question, the next planned trial will run for between six months and a year, testing skin biopsied from behind study participants ears.

In a tweet promoting the brand, Diamandis called it a longevity company, referencing a popular biotech concept that is attracting massive startup investment from billionaires.

We are seeing that the longevity space is growing; people will listen and learn more about what longevity is and expanding your health span and the importance of being healthier, said OneSkin co-founder and chief scientific officer Alessandra Zonari. She referenced the popularity of David Sinclair, the longevity-focused biologist focused on the concept of biological age. Gwyneth Paltrow is also interested in the concept, having her biological age calculated on the Netflix show Goop Lab.

OneSkin, meanwhile, has its own biological age calculator for skin called the MolClock (meaning molecular clock), which it developed in 2016. The concept was developed after three of the brands four co-founders worked together in a Brazil-based lab on 3D skin-tissue models, meant to serve as an accurate alternative to animal testing. That eventually developed into the creation of their first skin-care product.

We decided to focus on the anti-aging market that we saw was growing a lot, and its only going to grow. People are only getting older, but no one really knows which products work, said co-founder and CEO Carolina Reis Oliveira. Oliveira holds a PhD in immunology and worked in Brazil with fellow co-founders Mariana Boroni and Juliana Carvalho, who also each have PhDs.

The three co-founders relocated to the Bay Area in 2016 to create their startup through IndieBio. Zonari, who holds a PhD in skin regeneration and tissue engineering, joined the company in 2017 as the fourth co-founder. In 2018, they began the process of screening over 1,000 peptides in search of anti-aging properties and discovered OS-01.

The brand is betting that this biotech concept will catch on in the age-obsessed beauty world. We get overwhelmed about how many products that are out there, and you really dont know because there are all the claims saying that they rejuvenate, or that you will look younger, said Zonari.

The key for marketing to U.S. consumers is explaining the science in an accessible way. The brand will be focusing on content and education via social media promotions, especially through Instagram, as well as videos, webinars and Reddit groups dedicated to topics like longevity and age reversal. Reddits longevity group features an active and enthusiastic audience of over 64,000 members, who head to the message board to discuss topics related to biomedical rejuvenation, such as stem cell therapies, anti-cancer viruses, gene therapy, senolytics and whatever is coming next, according to the groups description.

We want to simplify this science in a way that people can connect with and can be easier to understand, said Oliveira. Basically, the way that we want to explain it is, OK, this peptide, its able to act in the molecular level of your skin in the deeper layers of your skin. How we differentiate is that most products only treat superficially.

IndieBio, SOSV Ventures, and 2Future Holding were the brands first investors for its seed round, when it raised just over $2 million in 2017. The brands most recent funding round occurred in July 2020, with an angel investment of $1.5 million, following a $3.5 million post-seed round in July 2019 from several angel investors.

Continue reading here:
Biotechs longevity obsession reaches the beauty industry - Glossy

Stem cells are believed to play a key role in hair loss – FLWL News

Using a brush or comb, in the shower, passing your hand through your hair In a 2015 IFOP survey, three out of four French people (76%) without baldness declared that they lost their hair. In addition, after 65 years, three in ten men suffer from androgenetic alopecia (or baldness). In general, therefore, we often see a loss of density with age, both in men and in women. However, science has long looked into the phenomenon of age-related hair loss, both to understand its origin and to treat it. Focusing on stem cells seems to offer the best hope for a cure, based on numerous studies.

The hair transplant procedure is indeed a sometimes expensive and invasive procedure. As for drugs, finasteride used for androgenetic alopecia in men can induce side effects such as loss of libido and erectile dysfunction while minoxidil can cause hypertrichosis. Today, researchers therefore seem to be looking more at alternative solutions, and in particular by focusing on stem cells.

Stem cells, directly linked to hair lossFor decades, researchers have always focused on keratinocytes, cells that make up the epidermis and integuments (body hair, hair, etc.). However, as part of a study conducted by the University of Calgary (Canada), the team of researchers focused on a small cell group present in hair follicles and in skin stem cells. : fibroblasts. And according to them, these fibroblasts are the main cause of age-related hair loss.

By studying the sparse coat of elderly mice, they noticed that fibroblast stem cells had lost their regenerative function or were malfunctioning. There werent enough of them to regenerate fibroblasts. As a result, the fibroblasts and hair follicles began to miniaturize and were no longer able to produce hair, explains Biernaskie, head of the research team.

Remember that fibroblasts are important because they send messages to keratinocytes to force them to divide, and in so doing, orchestrate the growth cycles of hair follicles allowing the production of new hairs. When the fibroblasts become scarce, the signal then becomes too weak to reach the keratinocytes and maintain the process of capillary growth. For Jeff Biernaskie: if we want to one day succeed in preventing hair loss or re-grow those that are already falling, we must work to preserve the function of these stem cells which are found in the hair follicles.

Against hair loss, but not only!This finding may help guide future research on hair loss more precisely. Scientists at the University of Calgary are particularly hoping to find a way to prevent this degeneration by blocking certain genetic mutations that occur directly in stem cells in fibroblasts.

They also believe that this will have wider implications. Indeed, Wisoo Shin, lead author of the study, points out that similar fibroblasts are found in most of our organs, maintaining their integrity and promoting tissue regeneration. Finding a way to promote self-renewal to produce new functional fibroblasts into old age therefore also offers the hope of being able to treat certain injuries and help the skin to regenerate.

Lamia spent a couple of years interning at an organization that offered medical consultation before joining the editorial team at FLWL News. An enthusiastic fitness freak in the room, she offers the best amounts of insights and craft-based writing style to keep us up to date about the medicine industry, health and science.

Email:lamia@flwl.orgPhone: +1 512-845-8162

See the article here:
Stem cells are believed to play a key role in hair loss - FLWL News

Brain organoids reveal neuronal flaws in syndrome tied to autism – Spectrum

Electric organoid: Neurons derived from people with 22q11.2 syndrome are hyperexcitable and show calcium-signaling deficits.

Courtesy of Pasca lab

Neurons derived from people with 22q11.2 deletion syndrome, a genetic condition linked to autism, show deficits in electrical activity and calcium signaling, according to a new study1. A single gene appears to be largely responsible for these defects, the study shows.

Up to 20 percent of people who lack part or all of the chromosomal region 22q11.2 have autism. Individuals with the deletion may also have schizophrenia, seizures, heart defects, immune dysfunction or learning problems.

The new findings uncover factors that may contribute to the development of psychiatric conditions associated with 22q11.2 deletion syndrome. They could also help researchers identify new therapeutic targets, says lead author Sergiu Pasca, associate professor of psychiatry and behavioral sciences at Stanford University in California.

The syndrome is relatively common, occurring in up to 1 in 4,000 newborns, Pasca says. But researchers do not fully understand how genes in the 22q11.2 region contribute to autism or other conditions, he adds.

To solve this molecular puzzle, Pasca and his team reprogrammed skin cells from 15 people with the deletion and 15 controls into induced pluripotent stem cells. Using a technique they developed in 2015, they coaxed these cells to turn into neurons, which self-organize in a dish into spherical clusters called organoids. The organoids show some key features of the developing cerebral cortex, a brain region implicated in autism.

The neurons derived from people with 22q11.2 syndrome spontaneously fire four times as frequently as neurons derived from controls, the researchers found. And the electrical activity of the 22q cells does not set off the usual spike in calcium levels, which is crucial for neurons to exchange messages.

In some other syndromes tied to schizophrenia and autism, calcium-channel genes are mutated. But the number of channels and the speed at which they work in 22q neurons is the same as in control neurons. Instead, the 22q cells show an unusually low voltage difference across the cell membrane when they arent firing, causing the signaling defects and hyperexcitability, the researchers found.

The researchers suspected that a gene called DGCR8 might be responsible for the neuronal deficits in the organoids because it lies within 22q11.2 and is linked to abnormal electrical activity in the neurons of mice2. DGCR8 is essential for the synthesis of short RNA fragments, called microRNAs, that regulate gene expression.

Lowering DGCR8s expression levels in control neurons reproduced the abnormalities seen in 22q neurons. In contrast, boosting the genes activity in 22q neurons or treating them with antipsychotic drugs prevented them from being overly excitable and reversed their calcium-signaling defects. The study was published 28 September in Nature Medicine.

Previous studies have analyzed lab-grown neurons derived from people with schizophrenia or autism-related disorders such as Rett and fragile X syndromes. But most used only a few human-derived cell lines, says Guo-li Ming, professor of neuroscience at the University of Pennsylvania in Philadelphia. The new study, Ming says, has a total of 30 human lines thats a huge effort.

By studying brain organoids derived from so many people, the researchers were able to identify the gene that might be involved in the psychiatric conditions associated with 22q11.2 syndrome, says Sally Temple, scientific director of the Neural Stem Cell Institute in Rensselaer, New York. Whenever we have a light shining ahead, saying, This is what you should really be looking at, it means that were making progress, she says.

The study participants with 22q11.2 syndrome vary in their psychiatric diagnoses, and yet all the brain organoids derived from their cells show the same neuronal abnormalities. Thats somewhat surprising, because we know there are a lot of differences in the genetic background of different people, Ming says.

The deletion might conspire with other factors to ultimately determine which psychiatric conditions a person has, Pasca says. It could be that the deletion causes cellular defects, and once there is a stressor such as social stress, disease develops. Its also unclear whether these cellular defects are related to the high prevalence of seizures in people with 22q11.2 syndrome, he says.

The hallmarks of most neuropsychiatric conditions can change over time, says Giuseppe Testa, director of the stem cell epigenetics unit at the European Institute of Oncology in Milan, Italy. Studies that look at a larger number of people with 22q11.2 deletion syndrome or other neurodevelopmental conditions could help to elucidate the relationship between the neuronal defects observed in the lab and the psychiatric manifestations of the conditions, Testa says. The new study, however, is a great resource for understanding how the 22q11.2 deletion contributes to schizophrenia and autism, he says.

Pascas team is trying to pinpoint molecules that could open new therapeutic avenues for 22q11.2 deletion syndrome. The antipsychotics they tested restore the unusual voltage differences in the 22q neurons, but they dont address the core mechanisms responsible for psychiatric conditions linked to the syndrome, Pasca says.

Whats more, antipsychotics have many side effects, and not all individuals respond to them, he says. We need better therapies we need to identify what the key molecular players are and target those.

Here is the original post:
Brain organoids reveal neuronal flaws in syndrome tied to autism - Spectrum

Astellas and Seagen Announce Positive Topline Results from Second Cohort of Patients in Phase 2 Pivotal Trial of PADCEV (enfortumab vedotin-ejfv) in…

TOKYO and BOTHELL, Wash., Oct. 12, 2020 /PRNewswire/ --Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Seagen Inc. (Nasdaq: SGEN) today announced positive topline results from the second cohort of patients in the pivotal phase 2 single-arm clinical trial known as EV-201. The cohort is evaluating the antibody-drug conjugate PADCEV (enfortumab vedotin-ejfv) for patients with locally advanced or metastatic urothelial cancer who have been previously treated with a PD-1/L1 inhibitor and have not received a platinum-containing chemotherapy and are ineligible for cisplatin. Results showed a 52 percent objective response rate (ORR) [95% Confidence Interval (CI): 40.8, 62.4] per blinded independent central review and a median duration of response of 10.9 months. The most frequently reported treatment-related adverse events Grade 3 or greater that occurred in more than 5 percent of patients were: neutropenia, rash, fatigue, increased lipase, diarrhea, decreased appetite, anemia and hyperglycemia. Data from cohort 2 of the trial will be submitted for presentation at an upcoming scientific congress and will be discussed with regulatory authorities.

PADCEV is a first-in-class antibody-drug conjugate (ADC) that is directed against Nectin-4, a protein located on the surface of cells and highly expressed in bladder cancer.1,2 The U.S. Food and Drug Administration (FDA) granted accelerated approval to PADCEV in 2019 based on results from the first cohort in this trial, which included patients whose disease hadprogressed during or following platinum-based chemotherapy and a PD-1/L1 inhibitor.

"Advanced urothelial cancer in patients who have received immunotherapy and are ineligible for cisplatin is a particularly difficult disease to treat," said Arjun Balar, M.D., Associate Professor of Medicine, Director Genitourinary Medical Oncology Program, NYU Laura and Isaac Perlmutter Cancer Center, NYU Langone Health and an investigator for the trial. "Typically, these patients are frail, suffer from multiple comorbidities beyond their urothelial cancer and are not able to tolerate additional treatment beyond immunotherapy, leading many to discontinue therapy altogether."

"We are committed to developing new treatments for patients with hard-to-treat cancers, such as those with locally advanced or metastatic urothelial cancer that has progressed following treatment with a PD-1 or PD-L1 inhibitor and who are ineligible for cisplatin therapy," said Andrew Krivoshik, M.D., Ph.D., Senior Vice President and Oncology Therapeutic Area Head, Astellas. "We look forward to discussing these data with regulatory authorities including the FDA."

"This is the first trial to report objective responses in patients with advanced urothelial cancer who had previously received immunotherapy but were ineligible for cisplatin in this setting due to inadequate kidney function or other conditions," said Roger Dansey, M.D., Chief Medical Officer at Seagen. "These promising new data from EV-201 may support a regulatory application to extend use of PADCEV in U.S. patients whose cancer has progressed after immunotherapy and who are ineligible for cisplatin."

Urothelial cancer is the most common type of bladder cancer (90 percent of cases), and can also be found in the urothelial cells that line the renal pelvis (where urine collects inside the kidney), ureter (tube that connects the kidneys to the bladder) and urethra.3 Globally, approximately 580,000 people will be diagnosed with bladder cancer in 2020, and bladder cancer will be attributed to approximately 210,000 deaths worldwide.4

About the EV-201 TrialThe EV-201 trial (NCT03219333) is a single-arm, pivotal phase 2 clinical trial of enfortumab vedotin for patients with locally advanced or metastatic urothelial cancer who have been previously treated with a PD-1 or PD-L1 inhibitor, including those who have also been treated with a platinum-containing chemotherapy (cohort 1) and those who have not received a platinum-containing chemotherapy in this setting and who are ineligible for cisplatin (cohort 2). The trial enrolled 128 patients in cohort 1 and 91 patients in cohort 2 at multiple centers internationally.5 The primary endpoint is confirmed objective response rate per blinded independent central review. Secondary endpoints include assessments of duration of response, disease control rate, progression-free survival, overall survival, safety and tolerability.

For more information about the EV-201 clinical trial, please visit clinicaltrials.gov.

About PADCEV (enfortumab vedotin-ejfv)PADCEV was approved by the U.S. Food and Drug Administration (FDA) in December 2019 and is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a platinum-containing chemotherapy before (neoadjuvant) or after (adjuvant) surgery or in a locally advanced or metastatic setting. PADCEV was approved under the FDA's Accelerated Approval Program based on tumor response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.1

PADCEV is a first-in-class antibody-drug conjugate (ADC) that is directed against Nectin-4, a protein located on the surface of cells and highly expressed in bladder cancer.1,2 Nonclinical data suggest the anticancer activity of PADCEV is due to its binding to Nectin-4 expressing cells followed by the internalization and release of the anti-tumor agent monomethyl auristatin E (MMAE) into the cell, which result in the cell not reproducing (cell cycle arrest) and in programmed cell death (apoptosis).2 PADCEV is co-developed by Astellas and Seagen.

PADCEV Important Safety Information

Warnings and Precautions

Adverse ReactionsSerious adverse reactions occurred in 46% of patients treated with PADCEV. The most common serious adverse reactions (3%) were urinary tract infection (6%), cellulitis (5%), febrile neutropenia (4%), diarrhea (4%), sepsis (3%), acute kidney injury (3%), dyspnea (3%), and rash (3%). Fatal adverse reactions occurred in 3.2% of patients, including acute respiratory failure, aspiration pneumonia, cardiac disorder, and sepsis (each 0.8%).

Adverse reactions leading to discontinuation occurred in 16% of patients; the most common adverse reaction leading to discontinuation was peripheral neuropathy (6%). Adverse reactions leading to dose interruption occurred in 64% of patients; the most common adverse reactions leading to dose interruption were peripheral neuropathy (18%), rash (9%) and fatigue (6%). Adverse reactions leading to dose reduction occurred in 34% of patients; the most common adverse reactions leading to dose reduction were peripheral neuropathy (12%), rash (6%) and fatigue (4%).

The most common adverse reactions (20%) were fatigue (56%), peripheral neuropathy (56%), decreased appetite (52%), rash (52%), alopecia (50%), nausea (45%), dysgeusia (42%), diarrhea (42%), dry eye (40%), pruritus (26%) and dry skin (26%). The most common Grade 3 adverse reactions (5%) were rash (13%), diarrhea (6%) and fatigue (6%).

Lab AbnormalitiesIn one clinical trial, Grade 3-4 laboratory abnormalities reported in 5% were: lymphocytes decreased (10%), hemoglobin decreased (10%), phosphate decreased (10%), lipase increased (9%), sodium decreased (8%), glucose increased (8%), urate increased (7%), neutrophils decreased (5%).

Drug Interactions

Specific Populations

For more information, please see the full Prescribing Information for PADCEV here.

About Astellas Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+ healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website athttps://www.astellas.com/en.

About Seagen Seagen Inc. is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people's lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on our marketed products and robust pipeline, visit http://www.seagen.com and follow @SeagenGlobal on Twitter.

About the Astellas and Seagen CollaborationAstellas and Seagen are co-developing PADCEV (enfortumab vedotin-ejfv) under a collaboration that was entered into in 2007 and expanded in 2009.

Astellas Cautionary NotesIn this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development), which is included in this press release is not intended to constitute an advertisement or medical advice.

Seagen Forward Looking StatementsCertain statements made in this press release are forward looking, such as those, among others, relating to the submission of data from cohort 2 of the EV-201 trial for presentation at an upcoming scientific congress; intended regulatory actions, including the potential submission of a regulatory application to extend the use of PADCEV in U.S. patients or plans to discuss data from cohort 2 of the EV-201 trial with regulatory authorities; and the therapeutic potential of PADCEV, including its efficacy, safety and therapeutic uses. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include that the data from cohort 2 of the EV-201 trial may not be selected for presentation at scientific congresses; the possibility of delays in the submission of any regulatory application to extend the use of PADCEV in U.S. patients; that the results from cohort 2 of the EV-201 trial may not be enough to support any approvals by regulatory authorities; that any product labeling that is approved may be narrower or less desirable than anticipated; the risk of adverse events or safety signals; and the possibility that adverse regulatory actions may occur. More information about the risks and uncertainties faced by Seagen is contained under the caption "Risk Factors" included in the company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 filed with the Securities and Exchange Commission. Seagen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

1PADCEV [package insert]. Northbrook, IL: Astellas, Inc.

2Challita-Eid P, Satpayev D, Yang P, et al. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models. Cancer Res 2016;76(10):3003-13.

3American Society of Clinical Oncology. Bladder cancer: introduction (10-2017). https://www.cancer.net/cancertypes/bladder-cancer/introduction. Accessed 05-09-2019.

4International Agency for Research on Cancer. Cancer Tomorrow: Bladder. http://gco.iarc.fr/tomorrow. Accessed 07-31-2020.

5ClinicalTrials.gov Identifier: NCT03219333. A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer (EV-201). https://clinicaltrials.gov/ct2/show/NCT03219333. Accessed on 08-03-2020.

SOURCE Astellas Pharma Inc.

http://www.us.astellas.com

More here:
Astellas and Seagen Announce Positive Topline Results from Second Cohort of Patients in Phase 2 Pivotal Trial of PADCEV (enfortumab vedotin-ejfv) in...

AIVITA Biomedical’s Stem Cell Therapeutic in Vision Loss Published in Investigative Ophthalmology & Vision Science – PRNewswire

IRVINE, Calif., Oct. 9, 2020 /PRNewswire/ --AIVITA Biomedical, Inc., a private biotechnology company developing personalized vaccines for the treatment of cancer and COVID-19, announced today the publication of the peer-reviewed manuscript, "Retina organoid transplants develop photoreceptors and improve visual function in RCS rats with RPE dysfunction,"in the journal Investigative Ophthalmology & Visual Science. The study, led by researchers at AIVITA Biomedical and the Sue & Bill Gross Stem Cell Research Center of the University of California, Irvine, used 3D-retina organoids generated from human stem cells developed by AIVITA to provide insight into the potential use of transplanted retina organoids as a therapeutic option for blinding diseases.

In the study, transplanted retina organoid sheets were examined to determine if human stem cell-derived photoreceptors coulddevelop, survive and function in vivo without the support of healthy retina pigment epithelium (RPE). Visual function was examined through a variety of tests, including optokinetic testing (OKT), electroretinogram (ERG), and superior colliculus (SC) brain recording. These tests concluded that retina organoid transplantations demonstrated significant improvement in visual function compared to non-surgery and sham surgery controls, supporting the application of AIVITA's stem cell technologies in visual disease therapeutics.

"Leveraging our expertise in stem cell growth and differentiation, I'm excited to see the promise of our technology platform in potential therapeutics for vision loss," said Hans Keirstead, Ph.D., chief executive officer of AIVITA and a contributing author to the paper. "To our knowledge, this study is the first to show that it's possible for photoreceptors derived from stem cells to survive and function after transplantation when a host has a dysfunctional RPE."

This work is supported by funding from the California Institute for Regenerative Medicine (CIRM) and National Institutes of Health (NIH).

About AIVITA Biomedical AIVITA Biomedical is a privately held company engaged in the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. Founded in 2016 by pioneers in the stem cell industry, AIVITA Biomedical utilizes its expertise in stem cell growth and directed, high-purity differentiation to enable safe, efficient and economical manufacturing systems which support its therapeutic pipeline and commercial line of skin care products. All proceeds from the sale of AIVITA's skin care products support the treatment of people with cancer.

SOURCE AIVITA Biomedical, Inc.

See original here:
AIVITA Biomedical's Stem Cell Therapeutic in Vision Loss Published in Investigative Ophthalmology & Vision Science - PRNewswire

U of T’s Medicine by Design invests $1 million to advance new ideas in regenerative medicine – News@UofT

Patients with cystic fibrosis experience recurrent lung infections that eventually destroy their airways, shortening their average life expectancy to 50 years in Canada. Current drug treatments, which target a malfunctioning pathway in cells that causes the infections, are costly and have varying effectiveness.

Now, with funding from Medicine by Design, a researcher at the Hospital for Sick Children (SickKids) is combining stem cells, gene editing and computational modelling to try to hijack an alternative cell pathway in the hopes of restoring lung function in these patients.

If successful, our study will be the first to provide proof-of-concept that this alternative approach to treating cystic fibrosis is effective, saysAmy Wong, a scientist working in developmental and stem cell biology at SickKids who is also an assistant professor in the department of laboratory medicine and pathobiology in the University of Torontos Temerty Faculty of Medicine.

Wongs project is one of seven across U of T and its affiliated hospitals that have been awarded 2020New Ideas AwardsandSeed Fundawards from Medicine by Design. Through a $1 million investment, Medicine by Design is supporting research aimed at advancing new concepts expected to be important to regenerative medicine in the coming years. The funded projects will have potential impacts in diseases and conditions such as vision loss, amyotrophic lateral sclerosis (ALS), intestinal disease in premature babies and more.

Supporting novel strategies and approaches is crucial to moving regenerative medicine into the future, saysMichael Sefton, executive director of Medicine by Designand a University Professor at U of Ts Institute of Biomedical Engineeringand thedepartment of chemical engineering & applied chemistry in the Faculty of Applied Science & Engineering.

Our 2020 New Ideas project portfolio integrates mathematical modelling, physics and computational biology with stem cell biology and biomedical engineering, and strengthens engagement with clinicians who are key to translating our research into patient impact. We are particularly delighted this year to support so many outstanding early-career researchers, who will ensure Toronto remains a global leader in regenerative medicine for years to come.

Wong is one of three investigators to receive a 2020 New Ideas Award, which is valued at $100,000 per year for up to two years. Four additional projects were selected for Seed Fund Awards of $100,000 each for one year to further develop their potential.

Medicine by Design selected the funded projects from among 36 short-listed proposals, which were evaluated and ranked through an external peer review process. Applications were submitted by clinicians and researchers at U of T and its affiliated hospitals from a wide range of disciplines including biochemistry, biomedical engineering, developmental and stem cell biology, immunology, neuroscience and surgery.

Medicine by Design builds on decades of made-in-Canada excellence in regenerative medicine dating back to the discovery of stem cells in the early 1960s by Toronto researchers James Till and Ernest McCulloch. Regenerative medicine uses stem cells to replace diseased tissues and organs, creating therapies in which cells are the biological product. It can also mean triggering stem cells that are already present in the human body to repair damaged tissues or to modulate immune responses. Increasingly, regenerative medicine researchers are using a stem cell lens to identify critical interactions or defects that prepare the ground for disease, paving the way for new approaches to preventing disease before it starts. Medicine by Design is made possible thanks in part to a $114-million grant from theCanada First Research Excellence Fund.

Current cystic fibrosis drug treatments target a genetic mutation that causes epithelial cells, which line the airway and act as a barrier against viruses, to function improperly. The mutation affects the function of an important ion channel in cells, called CFTR, which helps to maintain the right balance of fluid in the airways. Poor function causes mucosal obstructions in the airways and prevents clearance of foreign pathogens, which leads to chronic infections and ultimately destroys airway tissue.

In her project, Wong will explore an alternative ion channel in the epithelial cells to determine if it can be hijacked and used to compensate for the lack of function caused by the mutant CFTR. The research will be conducted using a combination of stem cell-derived lung models, gene editing and computational modelling.

Wongs project builds on decades of cystic fibrosis research at SickKids, where the cystic fibrosis gene was first identified 30 years ago.

To date, more than 2,000 mutations in the cystic fibrosis gene have been identified, says Wong. SickKids scientists and U of T researchers have become the epicentre of incredible cystic fibrosis research to understand how this disease works at the genetic and molecular level.

Wong says that, while the idea of targeting an alternative pathway is not necessarily ground-breaking on its own, its the array of tools now available that makes the idea a potential game changer.

We have access to an incredible resource of primary cells and stem cells from more than 100 individuals with cystic fibrosis harbouring various mutations. Wong says.Our lab has developed human lung models from stem cells that can be used to model lung disease such as cystic fibrosis. And with new advanced tools in single-cell genomics and gene-editing, coupled with key collaborations for computational modelling, we are poised to find new therapeutic targets for cystic fibrosis.

Leo Chou, an assistant professor at the Institute of Biomedical Engineering, andHyun Kate Lee, an assistant professor in the department of biochemistry in the Temerty Faculty of Medicineboth Medicine by Design New Investigators are also leading 2020 New Ideas projects.

Chou, along with co-investigatorsJulie Lefebvre, a scientist at SickKids and U of T assistant professor of molecular genetics, andValerie Wallace, a senior scientist at the Krembil Research Institute, University Health Network and a U of T professor of laboratory medicine and pathobiology and ophthalmology, will focus on cell transplantation in the retina, a process that has demonstrated encouraging pre-clinical results such as partial vision restoration in several animal disease models.

Recent research had demonstrated that this restoration is a result of the transfer of proteins complex molecules required for the structure, function and regulation of the bodys tissues between host tissue and donor cells. But the scope of that transfer process is not well understood. Chous project will develop an imaging approach to detect the transfer of mRNA molecules between host and donor cells. The outcomes from this project will inform the future design of cell transplantation therapies and lead to novel methods to deliver therapeutics. This project could improve therapies for retinal diseases and visual impairments, and inform strategies for other degenerative disorders.

Lee and co-investigatorPenney Gilbert,an associate professor at the Institute of Biomedical Engineering, will look at a common but not well-understood structure called the neuromuscular junction (NMJ), which mediates communication between neurons and muscles throughout the body. Defects in NMJ integrity and function underlie fatal diseases such as ALS. NMJ diseases, which affect more than 500,000 people globally, lack effective treatments. This project will use stem cells derived from reprogrammed skin cells of healthy people to develop NMJs in culture. Through high-resolution imaging, the healthy human NMJs will be studied both on their own and along with NMJs built from ALS patient cells. Through this work, the research team aims to identify genes to target to improve the health of NMJs, which could eventually help prevent or delay NMJ degeneration and even promote regeneration.

Michael Garton, an assistant professor at the Institute of Biomedical Engineering, has received a Seed Fund award to tackle the challenge of translating the genetic tools of synthetic biology an area of research that aims to create or redesign biological components using engineering methods into effective medical therapies against a number of diseases.

But they are difficult to translate into human therapies, Garton says, because the bodys T-cells immune cells that detect and destroy cells containing foreign material will identify these tools as foreign and destroy them.

Instead of switching off the T-cells, Gartons goal is to use computational modelling and high-throughput screening to selectively turn off the bodys foreign antigen display system so the immune system will still respond to foreign invaders when necessary, but allow cells containing synthetic tools to survive. If successful, this approach could enable a new generation of synthetic biology-enhanced cell therapies for a range of diseases.

Medicine by Design funding will help to facilitate the integration of synthetic biology and regenerative medicine and aid the development of cell-based therapies that perform better than nature, says Garton.

Other Seed Fund projects will encompass research in repairing the heart after paediatric cardiac surgery, treating an intestinal emergency in premature babies and creating a database for cell lineage paths.

John Parkinson, a senior scientist at SickKids and a U of T professor of biochemistry and molecular genetics, along with co-investigatorsJason Maynes, Wasser Chair in Anesthesia and Pain Medicine at SickKids and a U of Tassociate professor of anesthesiology and biochemistry, andWilliam Navarre, an associate professor in the department of molecular genetics, will investigate manipulating the microbiome, or community of microorganisms in the gut, to improve cardiac repair in post-operative treatment of a congenital heart disorder. Through a process that will identify prebiotics in breast milk that help enhance the production of molecules that research has shown can aid cardiac repair, the team will organize both observational (how disease alters the microbiome) and interventional (how the microbiome alters the disease) multi-site trials, which will provide the opportunity to immediately translate findings into changes in patient care regimens and improve outcomes.

CliniciansAgostino Pierro, a surgeon at the Division of General and Thoracic Surgery at SickKids and a U of T professor of surgery and physiology, and Philip Sherman, a senior scientist and gastroenterologist at the Division of Gastroenterology, Hepatology and Nutrition at SickKids and U of T professor of dentistry, pediatrics and laboratory medicine and pathobiology, have proposed a novel way of enhancing gut repair for a common intestinal emergency in premature babies, called necrotizing enterocolitis (NEC). A leading cause of death for these infants, NEC causes complications such as blindness, intellectual disability, repeat hospitalizations and gut damage even in those that survive. This project will look at whether intestinal organoids organ-like structures grown in the laboratory from stem cells that mimic some of the functions of native intestines can potentially stimulate repair of the gut and recovery from NEC. The project will define how to best transplant organoids, identify how the organoids protect the intestine from injury and assess if organoid transplantation is a valid new treatment for NEC.

Lincoln Stein, who is head of adaptive oncology at the Ontario Institute for Cancer Research and a professor in the department of molecular genetics at U of T, has received seed funding to build a database called Cytomics Reactome, which will be freely available to Canadian and international researchers. The database will build on recent technologies that open the door to the possibility of deciphering cell lineage paths the series of steps that lead a young, undifferentiated cell into a specialized one at single-cell resolution. To accelerate the path from basic research to clinical application, the database will systematically organize pre-existing knowledge of cell lineage paths into a comprehensive, interactive and easily accessible map that can serve as a framework for interpretation and integration of the latest experimental findings.

Read the original post:
U of T's Medicine by Design invests $1 million to advance new ideas in regenerative medicine - News@UofT

Discover The Augustinus Bader Wonder Cream Loved By The A List – Grazia

Two years ago I received an Augustinus Bader cream in a goody bag. I hadnt heard of it at the time, so paid little attention, although it looked nice enough a sleek, big blue bottle with rose gold accents. Shortly after, having just run out of my current moisturiser, I dug it out to give it a go. A few days later, forensically inspecting my skin in the mirror as I am wont to do in my more idle moments, I thought this stuff is actually really great. This was swiftly followed by another thought oh dear when I discovered it costs a whopping 205 a pop (for 50ml, you can get 15ml for 65). But it was too late, I was hooked. And that is how I became a woman who drops 205 on a moisturiser.

I am probably the least glamorous and definitely least well-known member of the Augustinus Bader fan club, which has swiftly reached legendary status in the beauty world and beyond. Kim Kardashian West, Naomi Campbell, Kate Bosworth, Priyanka Chopra and Diane Kruger all love the cult brand. Victoria Beckham invited Professor Bader to sit front row at her AW20 show; she also tapped his talents to collaborate with her on her debut skincare line (from seeing VB up close I can testify that this is a woman who knows good skincare, and the Cell Rejuvenating Power Serum is indeed excellent).

Professor Augustinus Bader and Victoria Beckham Getty

The latest addition to the Bader fan club is Emma Corrin. Prepping the new Diana for The Crowns Zoom press junket this week, her makeup artist Florrie White revealed she used The Cream and The Face Oil on the young actress. I use The Cream on everyone; me and my clients, White tells me. It instantly plumps and smooths the skin with three perfect pumps and creates a calm and luxurious base for every make-up look. Everyone always comments on how lovely it feels on their skin.

Today Augustinus Bader is a cult phenomenon but the founder is a man who seems to be more at home in a laboratory than on a red carpet. A leader in stem cell biology, and head of stem cell research at the University of Leipzig, Professor Bader has spent over 30 years focusing on how reawakening these cells can aid the healing process in particular embarking on a mission to help burns victims. In 2008, Bader formulated a groundbreaking wound gel that could help heal third-degree burns without the aid of surgery or skin grafts.

It was this breakthrough that led to the founding of the skincare line. After all, if it could have this effect on serious injuries, imagine what the technology could do for those of us lucky enough to have run-of-the-mill skin niggles? The brand launched with two hero products: The Cream and The Rich Cream which, according to the brand literature, contain patented TFC8 (Trigger Factor Complex) technology, which supports the skins natural processes, leaving all skin types mature, dry, oily, or sensitive looking restored, renewed and regenerated.

I was useless at science at school and all this technical talk is pure gobbledygook to me. What I can tell you is what its done for me. My skin is super sensitive, I have eczema, and have found that Augustinus Bader creams genuinely help to soothe it when it is aggravated. I have found that since using it, my complexion appears clearer, more even and the Holy Grail of beauty dewy (despite drinking gallons of water a day, I have never achieved that before). My mum, who observes me with the scrutiny that only mothers do, confirms that my skin looks great (I am privvy only to this information because she thought it was a result of finally listening to her by stopping smoking and making the hours before midnight count). Is it expensive? Well, yes, theres no way around that. However, in much the same way that I think that an impeccably cut designer jacket earns its value back in cost per wear, I have found that since using The Cream and The Rich Cream my skincare regime has simplified.

Sure, theres an element of hype involved. I still find it thrilling to be In The Know about something. But, for me and my skin, Augustinus Bader lives up to it. Believe me, I wish it wasnt true (I am not snobby with beauty products, and would happily wax lyrical about a 5 wonder find if Id discovered one), but thats the 205 price I have to pay and Id say its worth it.

READ MORE: 'I Just Love The Way A Polished Lipstick Completes A Look': Victoria Beckham's New Posh Lipsticks Explained In Her Own Words

View post:
Discover The Augustinus Bader Wonder Cream Loved By The A List - Grazia

Gray Hair: What You Need to Know about Causes and Possible Prevention – Coveteur

Find out what the pros had to say.

You never forget your first. Grey hair, that is. Maybe you pluck it? Heck, its just oneout of sight, out of mind, right? Yeah, we know, you pluck one and five more grow back in its place, and then those five turn into tenyou get the idea. Nothing that a good dye job cant fix. That is, until a pandemic forces you into quarantine with no access to your colorist, and it becomes brutally apparent just how grey your hair actually is these days. This standoff between my stealthy foe and I got me thinking: We know we cant reverse grey hair, but can we slow its progression or delay its initial onset? I called on the pros to find out, but first, some basic hair biology.

Advertisement

A protein called melanin is responsible for the color of our hair, and the cells in the hair follicles that make melanin are called melanocytes. Melanocytes are made by stem cells in the root of the hair, says Dr. Morgan Rabach, board-certified dermatologist, assistant professor at Mount Sinai School of Medicine, and co-founder of LM Medical NYC, and over time the stem cells die out and stop making melanocytes, leaving us with no cells to color the hair.

The age at which we start to go grey varies and depends on many factors. Dr. Caroline Robinson, MD, FAAD, and dermatologist and founder of Tone Dermatology, believes there is likely a genetic tendency at play in most cases of greying hair, but, like many genetic tendencies, there are environmental factors that influence how these changes show up in each of us. Dr. Rabach concurs, adding that grey hair is a combination of genetics and lifestyle.

Premature greying is generally considered less than 20 years old and it is thought to be an inherited predisposition. However, premature greying can also be attributed to certain illnesses and deficiencies. Dr. Robinson notes the importance of annual physicals and doctor visits when it comes to premature greying, as it could be an early sign of metabolic abnormalities in a select population.

Advertisement

Search results for grey hair yield a slew of information centered around the notion that going grey is a result of an accumulation of hydrogen peroxide in the follicle, and that it could be eradicated by a topical pseudocatalase cream. This claim seems to have originated from a segment of research on vitiligo, which then appeared to have been manipulated for headlines. Dr. Robinson weighed in with her thoughts on the claim, saying, There are no double-blinded, controlled clinical studies to support the use of topical pseudocatalase-based creams for loss of pigmentation in hair.

Similarly, some products have appeared on the market claiming to re-pigment the hair, but the consensus among experts is that the claims are unfounded. I havent seen any convincing evidence for products that claim to reverse or prevent greying of the hair, says Holden.

We know all too well the havoc that stress wreaks on our overall health, but the type of stress were referring to here is oxidative stressthe imbalance of free radicals and antioxidants in the body, which leads to cell and tissue damage. In oxidative stress, free radicals damage our cells and tissues when our body doesnt have enough antioxidants to combat them, and in our hair, this oxidative stress can damage the cells that produce melanin, says Kate Holden, consultant trichologist.

The pros agree that oxidative stress plays a key role in the loss of hair pigmentation. From recent research we know that oxidative stress, the same type of stress that our skin faces in response to UV rays and pollution, can be an important factor in the loss of hair pigmentation, says Dr. Robinson. While oxidative stress occurs naturally in our bodies, environmental factors can increase its effects, such as alcohol, smoking, sugar and processed foods, cortisol levels, etc.

In addition, a recent study conducted by a group of Harvard researchers looked at the impact of stress (like, say, the kind you feel during a worldwide pandemic) on pigment-producing cells and found that the hyper-activation of the sympathetic nerves caused the depletion of melanocyte stem cells. Trichologist Leata A. Williams explains, When we are under stress, our bodies signal the fight-or-flight response, and it is the nerves that send the response to our hair follicles, causing the hair to grey.

Just think of how many world leaders have gone grey while in officethats the sympathetic nervous system depleting their hair follicles of melanocytes. And although most of us will never feel the stress of running a country, were still susceptible to the same greying effect from our everyday lives.

Advertisement

Unfortunately for us, the pros agree that there is no real evidence to suggest that we can turn back the clock and re-pigment or slow the greying of hair in any tangible way. What we can do, however, is engage in healthy lifestyle behaviors that promote our overall health, and increase our intake of antioxidants. Increasing antioxidant intake through foods in our diet (leafy veggies, fruit) has not directly been shown to impact greying hair, but it can help to decrease overall oxidative stress levels in the body, says Dr. Robinson, which is something she discusses with her patients.

Dr. Rabach agrees and adds that she believes that a stress-free and healthy lifestyle makes your whole body healthier, and this would be reflected in the youthfulness of your hair. While we may not be able to reverse or halt grey hairs from popping up, what is encouraging is Dr. Rabachs belief that through good hair health, nutritious diet, and stress management, we might be able to delay their initial appearance. Increasing your antioxidant intake, whether it be from your diet, a multivitamin, or even a product formulated for hair health, will be beneficial in reducing oxidative stress and may help delay the initial onset of grey hair, says Dr. Rabach, who also encourages the use of hair products with antioxidants.

According to Dr. Robinson, there are some reports that Platelet Rich Plasma (PRP) therapy an in-office procedure that involves scalp injection of a processed form of ones own bloodcan promote hair re-pigmentation or slow greying because of its ability to deliver growth factors to the the hair follicle. While it sounds promising, more data needs to be gathered to determine its efficacy as a hair treatment.

Bottom line: Dont waste your money on products that claim to turn back the clock on grey hair, and focus instead on increasing your antioxidant intake and mitigating the effects of oxidative stress. Here are a couple products to get you started.

$17

Dr. Rabach promotes the use of antioxidant-rich hair products to help protect against the effects of oxidative stress. Look for one that is formulated with powerful superfruits like goji, acai, and pomegranate, and includes biotin for the added hair-nurturing benefits.

Buy

$65

This ingestible powder is chock-full of antioxidant-rich superfoods, adaptogens, and a probiotic blend to help your body resist stress, support detoxification, and support immunity. Add a teaspoon to water or a cold beverage of your choice, and reap the benefits of this all-natural, whole-food blend and help fend off the effects of oxidative stress.

Buy

Read this article:
Gray Hair: What You Need to Know about Causes and Possible Prevention - Coveteur

SGEN: The 3 Top Biotech Stocks That Hedge Fund Managers LOVE – StockNews.com

The biotech industry has been soaring this year, with the SPDR S&P Biotech ETF (XBI) up 26.6% year to date so far. The race for a COVID vaccine has primarily driven this performance, but what if there was another segment of the biotech industry that top hedge fund managers are all going after right now? While many managers are known to take risks, its certainly worth looking into if there is a consensus between them.

The AlphaClone Alternative Alpha ETF (ALFA) tracks an index of equity securities that hedge funds have significant exposure to. The ETFs top three holdings are all biotech firms working on cancer drugs. While many investors have their attention on biotech and pharmaceutical companies working on a COVID vaccine, big money has been focused on the next big thing in biotech, the future oncology drug boom.

Cancer is the second leading cause of death in the U.S. behind heart disease. Almost everyone knows someone that has been affected by one of the many vicious types of cancer. There are now numerous companies focused on ways to treat and cure the various forms. While COVID is at the forefront, cancer is a long-term play. There is even an ETF that covers the cancer industry, the Loncar Cancer Immunotherapy ETF (CNCR), which is up over 39% over the last six months.

As the oncology drug market is expected to reach $394 billion by 2027, here are the three top cancer stocks based on a consensus of hedge fund managers: Seattle Genetics (SGEN), Fate Therapeutics (FATE), and Blueprint Medicines (BPMC).

Seattle Genetics (SGEN)

SGEN is a biotech firm focused on developing antibody-drug conjugates. Its lead lymphoma drug, Adcetris, has been performing quite well since it launched, and it is the primary growth driver for the company. The drugs label was also expanded, providing more revenue for the company. SGEN has been collaborating with Takeda (OTCMKTS:TKPHF), a Japanese pharmaceutical company, for the global development and commercialization of Adcetris.

In addition to Adcetris, the company has a promising pipeline of drug candidates for its antibody-drug conjugate (ADC) technology. In December, the FDA granted accelerated approval to Padcev to treat patients with metastatic bladder cancer, who were previously treated with a checkpoint inhibitor and platinum-based chemotherapy. This drug was created in collaboration with Astellas Pharma (OTCMKTS:ALPMF), another pharmaceutical company.

In April, the FDA approved Tukysa for the treatment of metastatic HER2-positive breast cancer. Investors should also be happy with the news Merck (MRK) plans to buy a 2.9% stake in SGEN. The companies are co-developing and selling SGENs breast cancer therapy, ladiratuzumab vedotin.

The company is rated a Strong Buy in our POWR Ratings system, with a grade of A in Trade Grade, Buy & Hold Grade, and Peer Grade. Those are three out of the four components that make up the POWR Ratings. The stock is also ranked #2 out of 377 Biotech stocks.

Fate Therapeutics (FATE)

FATE is a clinical-stage biopharmaceutical company engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The company has been building up its pipeline of immuno-oncology product candidates. These treatments are designed to elicit an immune response in patients with cancer.

The companys progress with FT596 is encouraging. FT596 is cell cancer immunotherapy derived from its iPSC line. The induced pluripotent stem cell (iPSC) platform provides a competitive advantage for the company as iPSC cells are stem cells that can become almost any cell type. They are grown from the same cell instead of a patients donated cells. This means that one engineered cell line can be manufactured for many patients, creating what is known as off the shelf immunotherapy.

If the development of this type of therapy is successful, this would reduce the cost of manufacturing and provide a potential cash cow for the company. FATE has entered into collaborations with other companies for fund and research expertise. It is currently working with Ono Pharmaceutical (OTCMKTS:OPHLY) for two off-the-shelf iPSC-derived CAR T-cell product candidates, and Janssen Biotech develop iPSC-derived CAR NK and CAR T-cell product candidates.

FATE is rated a Strong Buy in our POWR Ratings system. It holds a grade of A in Trade Grade, Buy & Hold Grade, and Peer Grade. It is also ranked #24 out of 377 stocks in the Biotech industry. The stock is up a whopping 145.3% after finishing the day up 6.7%.

Blueprint Medicines (BPMC)

BPMC is a biopharmaceutical company focused on improving patients lives with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer. The firms lead product, Ayvakit, was approved by the FDA in January to treat metastatic gastrointestinal stromal tumor. The drug generated $5.7 million in the second quarter, so its off to a good start.

The company is also looking to expand its label as it is being studied for advanced and smoldering forms of systemic mastocytosis, a condition where certain immune cells, called mast cells, build up under the skin and, or in the bones, intestines, and other organs. If approved for other labels, that should help drive further growth.

Last month, the FDA approved the companys second drug, Gavreto, for the treatment of RET fusion-positive NSCLC or non-small lung cancer. BPMC worked on the drug with Roche (OTCMKTS:RHHBY). Lung cancer is responsible for more cancer deaths than any other in men and women. If Gavreto can become a standard treatment, it could become a goldmine for the company. The drug can also treat medullary thyroid cancers.

BPMC is rated a Strong Buy in our POWR Ratings system. It has grades of A in Trade Grade, Buy & Hold Grade, and Peer Grade. It is also the #9 ranked stock in the Biotech industry. The stock is up over 27% for the past three months and 8.5% over the past week.

Want More Great Investing Ideas?

7 Best ETFs for the NEXT Bull Market

What is the Cure for Stock Market Volatility?

Chart of the Day- See Christian Tharps Stocks Ready to Breakout

SGEN shares were unchanged in after-hours trading Friday. Year-to-date, SGEN has gained 75.72%, versus a 9.31% rise in the benchmark S&P 500 index during the same period.

David Cohne has 20 years of experience as an investment analyst and writer. Prior to StockNews, David spent eleven years as a Consultant providing outsourced investment research and content to financial services companies, hedge funds, and online publications. David enjoys researching and writing about stocks and the markets. He takes a fundamental quantitative approach in evaluating stocks for readers. More...

Go here to see the original:
SGEN: The 3 Top Biotech Stocks That Hedge Fund Managers LOVE - StockNews.com

The luxury skincare splurge that will help repair your skin cells – Dazed

Alex Peters is Dazed Beautys news writer. She picked up the phrase Its all happening from Almost Famous as a teen and it now exclusively makes up her vocabulary. Although in theory she likes the idea of a queer mullet, she is currently rocking the latest lockdown trend: Kajillionaire hair. Here, she shares her choice for Product of the Week a weekly round-up of the Dazed Beauty team and wider communitys must-have buys.

Brand: Augustinus Bader

Product: The Cream

Price: 205

As head of stem cell research at the University of Leipzig, Professor Augustinus Bader spent 30 years working with burns victims, developing a groundbreaking gel in 2008 that could heal third-degree burns without the need for skin grafts. Its this revolutionary stem cell technology the patented Trigger Factor Complex (TFC8) which lies at the heart of his skincare label and its hero product The Cream.

Powered by this technology, with consistent use (the Cream asks that you remain devoted to it for 27 days, using nothing else), the products activate and orchestrate the body's innate regenerative processes which basically means that when you use them your skin cells repair themselves. This helps with reducing the signs of ageing and environmental damage, reducing scarring and redness, and improving tone and texture.

Thats all very scientific, but the most important question is does it actually work? And for me it does. My skin is on the oily side as well as being sensitive and acne-prone so I use the Cream, rather than the Rich Cream which is better suited to dry skin types. The cream itself has a light texture that absorbs quickly and doesnt feel sticky. Two pumps is enough to cover your face and it goes on very smoothly. It has quite a distinctive scent, so if you are nose-sensitive be prepared. Its hard to describe clinical rather than artificial. It comes in a weighty blue and copper tube that feels fancy when youre using it.

I am not always great at using it consistently, particularly since we test out so many products as part of our job, but I have found that when I do, my skin looks noticeably better. My tone is more even and less red, the texture is better, scars look more faded, and I would tentatively say that it seems like I get fewer spots.

I would like to say, however, that the product is definitely on the higher end of the spectrum price-wise, and if you cannot afford it, please do not worry. There are a lot of great options out there that are more affordable and also very effective. If this is something that you can afford, I would highly recommend.

If I were communicating to an alien only using hand gestures, I would describe it with... Just a solid thumbs up. Or through elaborately miming the process of cell renewal.

It sounds like... A reassuring older German professor telling you efferyzing vill be alright and in the background the sound of a fire crackling.

If it was a meme it would be... Sorry to this man. Totally unrelated but its my favourite meme.

The fictional character who would use it is... Bette Porter from The L Word.

Alex Peters's Product of the Week

Go here to read the rest:
The luxury skincare splurge that will help repair your skin cells - Dazed

Citius Pharmaceuticals Signs an Exclusive Worldwide Licensing Agreement with Novellus Therapeutics for Unique iMSC-Therapy for Acute Inflammatory…

CRANFORD, N.J., Oct. 7, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company developing and commercializing critical care drug products, announced that it has signed an exclusive agreement with Novellus Therapeutics Limited ("Novellus") to license iPSC-derived mesenchymal stem cells (iMSCs), and has created a new subsidiary, NoveCite, that will be focused on developing cellular therapies.

NoveCite has a worldwide exclusive license from Novellus, an engineered cellular medicines company, to develop and commercialize NoveCite mesenchymal stem cells ("NC-iMSCs") to treat acute respiratory conditions with a near term focus on Acute Respiratory Distress Syndrome ("ARDS") associated with COVID-19. Several cell therapy companies using donor-derived MSC therapies in treating ARDS have demonstrated that MSCs reduce inflammation, enhance clearance of pathogens and stimulate tissue repair in the lungs. Almost all these positive results are from early clinical trials or under the emergency authorization program.

NC-iMSCs are the next generation mesenchymal stem cell therapy. They are believed to be differentiated and superior to donor-derived MSCs. Human donor-derived MSCs are sourced from human bone marrow, adipose tissue, placenta, umbilical tissue, etc. and have significant challenges (e.g., variable donor and tissue sources, limited supply, low potency, inefficient and expensive manufacturing). iMSCs overcome these challenges because they:

Globally, there are 3 million cases of ARDS every year out of which approximately 200,000 cases are in the United States. The COVID-19 pandemic has added significantly to the number of ARDS cases. Once the COVID patients advance to ARDS, they are put on mechanical ventilators. Death rate among patients on ventilators can be as high as 50% depending on associated co-morbidities. There are no approved treatments for ARDS, and the current standard of care only attempts to provide symptomatic relief.

"NoveCite iMSCs have the potential to be a breakthrough in the field of cellular therapy for acute respiratory conditions because of the high potency seen in Novellus' pre-clinical studies, and because iMSCs are iPSC-derived, and therefore overcome the manufacturing challenges associated with donor derived cells," said Myron Holubiak, Chief Executive Officer of Citius.

"We are excited to be part of this effort because of the promise to save lives and reduce long term sequelae in patients with devastating respiratory diseases such as ARDS caused by COVID-19," said Dr. Matthew Angel, Chief Science Officer of Novellus. "Our iMSC technology has multimodal immunomodulatory mechanisms of action that make it potentially promising therapy to treat acute respiratory diseases."

About Citius Pharmaceuticals, Inc.

Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. For more information, please visit http://www.citiuspharma.com.

About Novellus, Therapeutics, Limited

Novellus is a pre-clinical stage biotechnology company developing engineered cellular medicines using its patented non-immunogenic mRNA high specificity gene editing, mutation-free & footprint-free cell reprogramming and serum insensitive mRNA lipid delivery technologies. Novellus is privately held and is headquartered in Cambridge, MA. For more information, please visit http://www.novellus-inc.com.

About NoveCite iMSC (NC-iMSC)

NoveCite's mesenchymal stem cell therapy product is derived from a human induced pluripotent stem cell (iPSC) line generated using a proprietary mRNA-based (non-viral) reprogramming process. The NC-iMSCs produced from this clonal technique are differentiated from human donor-derived MSCs (bone marrow, placenta, umbilical cord, adipose tissue, or dental pulp) by providing genetic homogeneity. In in-vitro studies, NC-iMSCs exhibit superior potency and high cell viability. NC-iMSCs secrete immunomodulatory proteins that may reduce or prevent pulmonary symptoms associated with acute respiratory distress syndrome (ARDS) in patients with COVID-19. NC-iMSC is an allogeneic (unrelated donor) mesenchymal stem-cell product manufactured by expanding material from a master cell bank.

First generation (human donor-derived) MSCs are isolated from donated tissue followed by "culture expansion". Since only a relatively small number of cells are isolated from each donation, first generation MSCs are increased by growing the cells in culture. Unfortunately, these type of MSCs start to lose potency, and ultimately become senescent. Each donation produces a limited number of MSCs, so a continuous supply of new donors is needed to produce commercial scale. The number and quality of MSCs that can be isolated from different donors can vary substantially.

About Acute Respiratory Distress Syndrome (ARDS)

ARDS is an inflammatory process leading to build-up of fluid in the lungs and respiratory failure. It can occur due to infection, trauma and inhalation of noxious substances. ARDS accounts for approximately 10% of all ICU admissions and almost 25% of patients requiring mechanical ventilation. Survivors of ARDS are often left with severe long-term illness and disability. ARDS is a frequent complication of patients with COVID-19. ARDS is sometimes initially diagnosed as pneumonia or pulmonary edema (fluid in the lungs from heart disease). Symptoms of ARDS include shortness of breath, rapid breathing and heart rate, chest pain (particularly while inhaling), and bluish skin coloration. Among those who survive ARDS, a decreased quality of life is relatively common.

Safe Harbor

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: the risks associated with developing the NoveCite technology as a treatment for ARDS; risks associated with developing any of our product candidates, including any licensed from Novellus, Inc., including that preclinical results may not be predictive of clinical results and our ability to file an IND for such candidates; our need for substantial additional funds; the estimated markets for our product candidates, including those for ARDS, and the acceptance thereof by any market; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; the early stage of products under development, including the NoveCite technology; our ability to obtain, perform under and maintain licensing, financing and strategic agreements and relationships; our ability to attract, integrate, and retain key personnel; risks related to our growth strategy; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:Andrew ScottVice President, Corporate Development(O) 908-967-6677 x105(M) 646-522-8410ascott@citiuspharma.com

View original content:http://www.prnewswire.com/news-releases/citius-pharmaceuticals-signs-an-exclusive-worldwide-licensing-agreement-with-novellus-therapeutics-for-unique-imsc-therapy-for-acute-inflammatory-respiratory-conditions-including-covid-19-related-acute-respiratory-distress-syndrom-301147409.html

SOURCE Citius Pharmaceuticals, Inc.

Company Codes: NASDAQ-SMALL:CTXR

More here:
Citius Pharmaceuticals Signs an Exclusive Worldwide Licensing Agreement with Novellus Therapeutics for Unique iMSC-Therapy for Acute Inflammatory...

Who are the winners of the in-cosmetics Global Awards 2020? – Premium beauty

Despite the challenges brought about by Covid-19, leading cosmetic manufacturers, including Mibelle Biochemistry, Cargill Beauty, Givaudan Active Beauty and Lucas Meyer, put forward their most creative innovations for consideration by the in-cosmetics Global Awards jury.

Judged across three categories - Best Active Ingredient, Best Functional Ingredient and Best Green Ingredient - by some of the industrys foremost experts, the awards recognise the cosmetic ingredient manufacturers who are helping to push the boundaries of innovation, while responding to evolving consumer demands.

The winners were announced yesterday during a virtual ceremony from a list of finalists dominated by skin care ingredients.

Scooping both the Gold and Silver awards in the Best Active Ingredient category, Vytrus Biotech was recognised for its Kannabia Sense and Deobiome Noni ingredients.

Kannabia Sense took the top accolade. This probiotic treatment stimulates the skin microbiota to produce an in-situ postbiotic cocktail that promotes the synthesis of cutaneous oxytocin. Recommended for use in sensitive skin treatments, anti-ageing cosmetic products and delicate facial treatments, it is made from plant stem cells of Cannabis sativa.

Deobiome Noni is a prebiotic deodorant treatment that reduces the generation of body odour while allowing the skin to breathe and respecting the skin microbiota.

Closing the category, Mibelle Biochemistry and Clariant Active were announced as this years joint Bronze Award winners.

Alpine Rose Active, Mibelle Biochemistrys novel senolytics concept, was chosen for its ability to eliminate senescent skin cells and protect skin proteins from oxidative stress.

Clariant Active was applauded for Prenylium. Thanks to Clariants Plant Milking technology, Prenylium is extracted from the root of the mulberry tree (Morus Alba) without causing any damage. This innovative and sustainable approach to sourcing helps to stimulate root growth and results in a concentration of prenylated flavonoids 2000% higher than what is typically found in mulberry root extracts.

German cosmetic manufacturer Symrise took the top award in the Best Functional Ingredient category for its Symrise SymEffect Sun. Based entirely on renewable raw materials from responsible sources, the new ingredient combines the advantages of conventional sunscreen products with the increasing sustainability requirements of consumers.

Also demonstrating a sustainable approach to sun protection, Dow Chemical was awarded the Silver award for its SunSpheres BIO SPF Booster, a bio-based and readily biodegradable SPF boost that enables greater SPF efficiency in suncare and daily skincare products.

The category also honoured two bronze award winners: Clariant and Gattefoss. The former was awarded for Velsan Flex which, thanks to its high water solubility and Renewable Carbon Index (RCI) of 93%, offers preservation boosting powers together with broad formulation flexibility. Gattefosss Emulium Dolcea MB a natural origin O/W emulsifier - has the ability to create a wider range of textures, from fluid serum to thick butter in a wide range of applications, such as skincare, suncare, make up and haircare.

As sustainability continues to drive cosmetic manufacturers to assess the ingredients used in their formulations, this years Green Ingredient Award - in partnership with Ecovia Intelligence - recognises the ingredients championing sustainability in the personal care and beauty market.

Henry Lamotte Oils Paradise Nut Oil/Magdalena River Nut Oil scooped the Gold Award for its ability to support the regeneration of the skins lipid film, while improving the water retention capability of the skin, reducing trans-epidermal water loss.

Unveiled as the Silver Award winner, Cargill Beautys FiberDesign Sensation was praised for its approach to sustainability and upcycling. Derived from 100% natural origins, the texturiser and emulsion stabiliser, designed specifically for skincare, is based on citrus peel fibres from the pectin production side stream.

Joining the line-up of award winners, Minasolve SAS scooped the Bronze Award for its A-Leen Aroma-3, a nature-derived perfuming agent that also offers a broad-spectrum antimicrobial effect. It is a 100% natural version of phenylpropanol, it is produced from cassia essential oil.

Cosmetic Ingredients - October 2020

For more information on the latest cosmetic ingredients launches, also read our special issue:

How far will clean beauty go?

Interest in upcycled ingredients expected to rise in the cosmetics industry

Driven by new consumer preferences, demand for cupuau butter is on the rise

in-cosmetics Awards 2020

Ingredient news: Akott, BASF, Berkem, Clariant, Codif, Covestro, DSM, Firmenich, Givaudaun, Grolman, Imerys, Inter Actifs, Lubrizol, Mibelle, Sederma, Seppic, Silab, Symrise

Read online for free or download the pdf version here.

More here:
Who are the winners of the in-cosmetics Global Awards 2020? - Premium beauty

Archives